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ABSTRACT
CHARACTERIZATION OF HUMAN T-BET-EXPRESSING B LYMPHOCYTES AND THEIR
ROLE IN THE HIV IMMUNE RESPONSE

James J. Knox
Michael R. Betts

Humoral immunity is critical for the prevention and control of viral infections, yet the specific B
cells and mechanisms regulating antiviral responses in humans remain poorly defined. The Th1associated transcription factor T-bet coordinates intracellular pathogen immune responses, and
recent murine studies identified a T-bet-expressing B cell subset that mediates humoral antiviral
immunity, but an analogous cell population has not been identified in humans. In this study, we
sought to investigate the role of T-bet-expressing B cells during human viral infections. We
identified T-bet expression within the memory B cell compartment of healthy individuals and
described a relationship between the transcription factor and IgG1 and IgG3, two antiviral
+

antibody isotypes. The T-bet B cell population was comprised of two discrete subsets: T-bet
resting memory cells and a highly activated, transcriptionally distinct T-bet
atypical memory phenotype. The T-bet

high

high

low

subset displaying an

cell population transiently expanded in blood following

vaccination with yellow fever or vaccinia virus; however, these cells were induced and maintained
at an elevated frequency by chronic HIV viremia and were associated with increased expression
and secretion of IgG1 and IgG3. The HIV gp140-specific response was maintained almost
+

entirely by T-bet memory B cells in both viremic and aviremic donors. Together, our findings
+

identify T-bet is a critical regulator of humoral antiviral immunity in humans and suggest T-bet B
cells specifically mediate the humoral immune responses to live viral vaccines and HIV.
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CHAPTER 1	
  
INTRODUCTION

	
  
	
  
	
  
1.1 B cells and immunological memory: an introduction

B lymphocytes, or B cells, were first described as a separate lymphocyte lineage from T
cells in 1965 by Cooper et al., named as such for their bursa-dependent, versus thymusdependent, development in birds (1). A number of seminal studies established B cells as the
mediators of humoral immunity that give rise to plasma cells and ultimately regulate the
production of antibodies, soluble γ-globulin proteins that recognize pathogens (2). B cells and
antibodies are necessary for successful immune responses to various viruses, bacteria, fungi,
and parasites, mediating pathogen clearance directly by neutralization or in concert with the
innate and adaptive immune systems (3). The ability to harness humoral immunity through
vaccination stands as perhaps the greatest public health achievement, as vaccines have greatly
reduced the incidence of numerous infectious diseases and have eradicated smallpox (4).
Notably, nearly all licensed vaccines are thought to function primarily through the elicitation of
protective antibodies and B cell memory (4), highlighting the powerful capacity of the humoral
immune system to afford protection against invading pathogens.
One of the hallmarks of adaptive immunity is its ability to establish long-lived memory
cells capable of recognizing previously encountered antigens and inducing a focused
immunological response. Upon activation by their cognate antigens, mature T and B cells give
rise to a suite of antigen-experienced progeny, including effector cells that mediate the acute
response and long-lived memory cells that persist as sentinels prepared for re-infection (5). Upon
antigen re-encounter, memory B cells fulfill several functions that contribute to the immune
respnose: they are poised to quickly differentiate into antibody-secreting cells, but they also can
seed new germinal center reactions to further mature their B cell receptor via hypermutation and
isotype switching, processes that improve antigen binding affinity and increase the diversity of
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antibody effector functions (6). An improved understanding of B cell biology during the generation
of humoral immune responses will inform vaccine development and therapeutic interventions to
strengthen immunity.

1.2 Generation of humoral immunity

Early B cell Development
The lineages of all antigen-specific B cells can be traced back to the bone marrow. B cell
development in adults begins in the bone marrow, a niche with specific growth factors such as IL7 and other signals necessary to guide the differentiation of hematopoietic stem cells through
multipotent myeloid/lymphoid progenitor and common lymphoid progenitor stages, and finally into
the B cell lineage (7). Early B cell progenitors are restricted to the B cell lineage upon
upregulation of Early B cell Factor 1 (EBF1) and Paired Box 5 (Pax5), two transcription factors
that function within a broader transcriptional network to regulate the B cell developmental process
and its stepwise expression and rearrangement of the B cell receptor (BCR) genes (8, 9). B cell
precursors complete rearrangement of their VH, DH, and JH segments to form the BCR heavy
(IgH) chain and express it on the surface, where it can signal to promote allelic exclusion and, in
complex with the surrogate light chain as the pre-BCR, confirm the heavy chain’s ability to
complex with a light chain (10, 11). Surviving pre-B cells rearrange the VL and JL segments to
create the light (IgL) chain and finally join the heavy and light chains together to form a functional
BCR with an IgM constant region (12).
Newly formed immature B cells that are sufficiently non-self-reactive will egress from the
bone marrow into the periphery, where they are termed ‘transitional’ B cells (12, 13). Transitional
B cells undergo additional selection and maturation processes in secondary lymphoid tissue sites
such as the spleen, where their survival is dependent upon both BCR signaling strength and
concentrations of B lymphocyte stimulator (BLyS), a B cell survival factor. Appropriate signal
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combinations allow transitional B cells to seed the mature naïve B cell compartment (14, 15). The
resulting mature B cell pool demonstrates extraordinarily diverse antigen recognition potential
capable of engaging nearly any incoming pathogen or antigen. Naïve B cells, which account for
nearly half of all B cells in adults, therefore function as a reservoir of diverse BCR specificities
waiting to encounter their cognate antigen (11).

The initiation of humoral immune responses
In lymphoid tissues, naïve B cells recognize and bind their cognate antigen using
surface-expressed BCR. Antigen binding transduces activation signals via BCR-associated Igα
and IgΒ molecules containing immunoreceptor tyrosine-based activation motifs (ITAMs) and is
enhanced by concurrent activation of a co-receptor complex consisting of CD19, CD21, and
CD81 (16). Phosphorylation of ITAMs by Src-family tyrosine kinases recruits molecules such as
spleen tyrosine kinase, phospholipase Cγ2, and phosphoinositide 3-kinase to initiate signaling
cascades resulting in calcium mobilization, transcriptional activation, cytoskeletal rearrangement,
and internalization of BCR-antigen complexes (17). In vivo, this activation process often occurs in
the context of B cell-follicular dendritic cell (FDC) interactions and is facilitated by the formation of
an immunological synapse, a specialized structure concentrating multiple BCR-antigen and
signaling molecule complexes at the interface between the two cells (16).
B cells can subsequently undergo T cell-independent (TI) development, which results in
production of low-affinity plasmablasts and small numbers of memory B cells, or begin the T celldependent (TD) pathway. The TD activation process continues as B cells process and
subsequently present internalized antigens on major histocompatibility complex (MHC) molecules
to cognate T cells at sites such as the border of the T cell and B cell zones or the interfollicular
zone (17, 18). Here, B cells begin extended interactions with recently activated antigen-specific
+

CD4 T cells and proliferate (19). Several fates are possible following T cell interactions: 1) a
subset of activated B cells further migrate into extrafollicular regions and give rise to unswitched
memory B cells or short-lived plasmablasts that produce low-affinity antibodies, while 2)
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additional B cells begin the germinal center maturation pathway and eventually give rise to high
affinity memory B cells and plasma cells (19).
+

Both activated memory B cells and CD4 T cells destined to generate a germinal center
reaction undergo a differentiation process regulated in part by the transcription factor B cell
lymphoma protein 6 (Bcl-6; (20)). Alterations in homing receptor expression, including
upregulation of CXCR5 and downregulation of CCR7, permit the migration of these cells, now
referred to as germinal center (GC) B cells and T follicular helper (Tfh) cells, into the center of the
B cell follicle (21, 22). B cells congregate amongst follicular dendritic cells (FDCs), an antigenpresenting population, proliferate, and eventually form a large structure comprised of light and
dark zones (23). In the light zone, B cells compete for Tfh cell help: the process is dependent
upon BCR affinity, as high affinity B cells bind and uptake more antigen from FDCs, and
internalized antigens are processed and presented via MHC-II molecules to Tfh cells (24).
Increased antigen presentation correlates with greater Tfh help signaling in the form of cell-to-cell
contact (i.e. CD40-CD40L interactions) and helper cytokines (i.e. IL-21) that promotes B cell
survival (19). B cells receiving insufficient Tfh help undergo apoptosis, while B cell clones
obtaining Tfh help migrate into the dark zone, proliferate extensively, and simultaneously
introduce point mutations into the antigen binding regions of their BCR (19, 25). B cells can
migrate back into the light zone for additional Tfh help, and these iterative cycles of competition,
proliferation, and mutation improve BCR affinity for the antigen and ultimately select for highaffinity B cell clones (25). Isotype switching, the process of changing the expressed antibody
class from IgM to alternative isotypes with diverse functions, also takes place within the light zone
(26). Upon exiting the germinal center, high affinity GC-produced B cells can differentiate into
memory B cells or antibody-secreting cells (5).
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1.3 Antibodies and their function

Antibody-secreting cell fate decisions
Plasma cells and their immature precursors plasmablasts (collectively termed antibody
secreting cells (ASCs)) represent the terminal differentiation state of the B cell lineage and
function to constitutively produce and secrete antibodies (27). During early immune responses,
these cells derive from activated B cells via a GC-independent mechanism to generate lowaffinity antibodies as a first line of defense. As immune responses develop, longer-lived ASCs
with high-affinity antibodies are generated by T-dependent germinal center reactions (27, 28). In
both cases, adoption of the ASC fate requires partial suppression of B cell identity, which is
achieved by transcriptional repression of Bcl-6 and Pax5 by the transcription factor PR domain
zinc finger protein 1 (PRDM1, or BLIMP1; (29, 30)). Together with BLIMP1, the transcription
factors interferon regulatory factor 4 (IRF4) and X box binding protein 1 (XBP1) further promote
the ASC developmental program and drive plasmablast differentiation (31-33). Plasma cells
migrate to specific tissues such as bone marrow and gut-associated lymphoid tissue (GALT),
where they can persist for decades and continue to secrete protective antibody (34, 35).

Antibody structure and function
Antibodies (also known as immunoglobulins, or Ig) are globular proteins that exist either
in a cell membrane-expressed form as the BCR or in a soluble form within serum and at sites of
pathogen encounter such as mucosal surfaces. Antibodies are comprised of two identical sets of
heavy chains and light chains connected by disulfide bonds to form a distinctive Y-shape, with an
antigen binding region (Fab) at the two tips and a constant region (Fc) at the base that interacts
with immune system components (3). The Fab region contains variable domains with
complementarity-determining regions (CDRs) that directly interact with antigen, can be highly
mutated, and are interspersed between framework regions (FRs) that maintain domain structure
(3). Conversely, the Fc region lacks this mutational diversity but exists in several different isotypes
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that inform antibody function: IgM, IgD, IgA (two subtypes), IgG (four subtypes), and IgE .
Modifications such as glycosylation can further influence the functionality of each isotype by
affecting Fc receptor interactions and antibody half-life (36).
The utility of antibodies is based upon their ability to diversify their antigen binding
domains and switch their isotype classes, two processes that require activation induced cytidine
deaminase (AID; (37)). Functionally, this B cell-specific enzyme converts deoxycitidine (dC) to
deoxyuracil (dU) at targeted DNA sites, leading to induction of point mutations that facilitate
somatic hypermutation or double strand breaks that enable class switch recombination (37, 38).
AID expression is tightly regulated transcriptionally, post-transcriptionally, and at the protein level
by a number of factors in an effort to minimize AID activity at off-target genetic loci that could
cause cell transformation (38). Within the B cell compartment, AID is primarily expressed within
GC B cells but is upregulated following B cell activation can also be expressed during
extrafollicular B cell development (39). AID expression is critical for the development of high
affinity antibodies and memory B cells during immune responses (24, 40).
Antibodies function to mediate pathogen clearance in several ways that are directly
dependent upon AID-regulated somatic hypermutation and class switching. Antibodies can
directly neutralize pathogens by interfering with processes necessary for infection and
pathogenesis (e.g. preventing interaction between virions and cell surface receptors necessary
for viral entry (3)); neutralization is improved with affinity maturation and is generally independent
of the Fc region (41). Antibodies can also act as intermediaries via opsonization, the marking of
infected cells or pathogens for death or immune clearance. This process is dependent upon the
Fc region’s ability to activate the complement system and engage phagocytic cells and natural
killer cells that express Fc receptors (3, 42, 43). Different types of pathogens elicit specific
antibody isotypes to mediate relevant effector functions; human antibody isotype diversity will be
discussed below.
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Antibody isotypes
IgM is the first isotype B cells express during development (17). IgM is generally of low
affinity, demonstrating reduced rates of somatic hypermutation and increased polyreactivity
compared to other isotypes. To compensate for this, IgM is secreted in a pentameric complex
joined together by disulfide bonds to enable high avidity interactions with antigens (3). IgM is the
first serum antibody produced during an acute infection before germinal centers are fully
established; however, significantly mutated IgM can be produced by germinal center-derived
memory B cells and plasma cells later in the response (44). Functionally, IgM antibody can
opsonize antigens and efficiently activates the complement system, and evidence in humans
+

suggests a niche for IgM memory B cells in seeding secondary germinal center reactions at the
expense of undergoing plasma cell differentiation upon antigen re-encounter (45). Thus, IgM
plays an important role at multiple points during the course of both primary and secondary
infections.
The biological function of IgD remains unclear, as it is rarely secreted into the serum.
During development, IgD is first detected on naïve B cells, where it is co-expressed with IgM (17).
A recent study suggests IgD may chiefly function in a signaling capacity as a BCR on naïve cells,
as it recognizes multivalent antigens more efficiently than the IgM isotype (46). However, a
number of observations suggest wider roles for this antibody isotype: most IgM-expressing
+

memory cells continue to co-express IgD (6), class-switched IgD memory B cells (“IgD-only”) can
+

be found in peripheral blood at low frequencies (47), IgD plasma cells have been identified in
tonsils and the human upper airway (48), and secreted IgD has been shown to bind and activate
basophils (48).
IgA antibodies are critical components of mucosal immunity that can be secreted in a
dimeric structure. While detectable in serum at a titer equal to or greater than IgM, IgA is the most
prevalent isotype at mucosal surfaces and in secretions (3). The IgA class is comprised of IgA1
and IgA2 subtypes that differ structurally in their hinge regions, with IgA1 being prevalent in
serum and IgA2 in secretions. Plasma cells in GALT constitutively produce IgA that can be
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transported across intestinal epithelial cells via the polymeric Ig receptor into the lumen, where it
protects the epithelium from infection and regulates commensal bacteria populations (49).
Functionally, IgA mediates neutralization but does not efficiently activate complement or opsonize
antigens (3).
IgE mediates immune responses to helminths and plays a role in allergic responses.
+

While serum IgE levels and frequencies of IgE memory B cells in peripheral blood are low, IgE is
a potent activator of mast cells and basophils, which express the high affinity FceRI (50). The
interaction of FceRI-bound IgE with antigen leads to degranulation and release of inflammatory
mediators from mast cells that exacerbate allergic reactions (50). IgE also binds to a low affinity
FceRII receptor expressed on B cells, through which it regulates antibody production (51).
IgG class antibodies are the most prevalent in human serum, in part due to their long half
life. There are four subtypes, named in order of abundance (IgG1>IgG2, etc.), with distinct
structural and functional profiles (52). IgG1 and IgG3 are induced by protein antigens, particularly
in the context of a TD response, and are notable for their ability to engage effector cells: they
efficiently activate complement and bind to all three classes of FcγRs, although IgG3 generally
has higher affinity (3, 6, 52). As such, IgG1 and IgG3 isotypes are critical for antiviral responses
and are particularly inflammatory (52). IgG3 is produced during the early immune response to
viral infections and is eventually overshadowed by IgG1 as the response progresses (53, 54); the
+

gradual loss of IgG3 is based upon the structure of the Fc region locus (i.e. IgG3 memory cells
+

can switch to become IgG1 , but not vice versa) and IgG3’s reduced half-life compared to other
IgG isotypes (IgG1 outcompetes IgG3 for neonatal Fc receptor-mediated recycling (53)). In
contrast, IgG2 is critical for polysaccharide antigen responses, as evidenced by the association
between IgG2 deficiency and increased susceptibility to encapsulated bacteria infections. IgG2 is
+

often produced during TI immune responses, but many IgG2 memory B cells show evidence of a
germinal center origin (55, 56). IgG4 is a rare isotype that can be induced in a number of settings,
including polysaccharide antigen responses and settings of allergy (52). IgG2 and IgG4 poorly
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activate complement and have low affinity for most FcγRs; as such, they are relatively inefficient
opsonizers compared to the IgG1 and IgG3 isotypes (3).

1.4 Memory B cells

Memory B cell fate decisions
Like ASCs, memory B cells can also differentiate from T cell-independent (TI) or T celldependent (TD) immune responses, having either extrafollicular or germinal center origins in the
latter case (5). However, in contrast to ASCs, the molecular mechanisms regulating adoption of
memory B cell fate after germinal center exit are largely unclear. While a master transcription
factor akin to BLIMP-1 has not been identified, the transcriptional regulator BTB Domain and
CNC Homolog 2 (Bach2) may be important for memory differentiation (57, 58). Survival of the
germinal center reaction in the absence of ASC-inducing signals has also been proposed to
inherently promote assumption of the memory fate (59), and events predating this fate choice
such as isotype class switching may even affect memory differentiation (60). Regardless, the
memory B cell compartment functions as a reservoir of cells primed to respond to pathogen reencounter, orchestrating a rapid secondary response culminating in antibody production to
contain and clear the pathogen before widespread pathology can occur.
The memory B cell compartment is exceptionally diverse, a property reflected not only in
its expression of the different antibody isotypes, but also in the various origins, functions, and
phenotypes of its members. Despite this diversity, these cells are reliably identified by the
presence of antibody somatic hypermutation, isotype switching, and phenotypic signatures
associated with a post-germinal center state (6). In this dissertation, “memory B cells” will broadly
refer to the antigen-experienced B cells produced by immune responses that maintain the B cell
phenotype (i.e. excluding ASCs): this group includes both long-lived, quiescent cells and those
actively participating in the immune response.
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Memory B cell functions
Memory B cells fulfill a number of roles that both support developing immune responses
and contribute to pathogen clearance. The ability to readily differentiate into plasmablasts
producing high-affinity antibodies separates memory from naïve B cells and is perhaps the most
important function of B cell memory (6). Memory B cells can also re-enter and form new germinal
center reactions upon pathogen re-encounter, a process that diversifies the antigen-specific
antibody pool by further fine-tuning antibody affinity and broadening the isotype repertoire (61).
Via these mechanisms, memory B cells can increase the baseline volume of antibody produced
by existing plasma cells from the primary response and diversify the Fab region to facilitate
responses to mutating pathogens.
Memory B cells also contribute to the immune response with antibody-independent
functions. B cells highly express MHC-II molecules, which they use to present processed
+

antigens to CD4 T cells (16). Antigen presentation is an important feature of GC B cells that
facilitates interactions with Tfh cells in germinal centers to promote mutual activation,
proliferation, and differentiation (62), and subsets of post-germinal center B cells appear to be
efficient antigen presenters in specific tissue sites such as the mouse spleen (63). Memory B
cells also produce cytokines that shape the immune response: B cells can produce IL-12 and
IFNg, which promote Th1-type (intracellular pathogen) immune responses, or IL-4 and IL-13,
which promote Th2-type (extracellular parasite) immunity (64, 65). B cells produce additional
cytokines such as tumor necrosis factor and IL-6, and a subset of B cells, termed regulatory B
cells, produce the cytokines IL-10 and/or transforming growth factor beta to suppress immune
responses (66).

Human memory B cell phenotypes
Memory B cells are derived from naïve B cells following antigen-induced activation,
leading to the accumulation of mutations in antibody variable domains and (in some cases)
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+

+

switching from the IgM IgD isotype. Memory B cells were originally identified by the IgD

-

+

phenotype (67) until the discovery of somatically mutated IgD B cells suggested that isotype
expression was insufficient to delineate memory (68, 69). A correlation between somatic mutation
and CD27 expression was concurrently described, identifying CD27, a tumor necrosis factor
receptor family member, as a B cell memory marker in the spleen and peripheral blood (68, 69).
+

Appropriately, CD27 B cells were found to be larger, contained increased cytoplasm, and readily
differentiated into class-switched ASCs following antigen and/or cytokine stimulation (70).
Subsequent studies would identify memory B cell subsets that do not express CD27.
-

First, a peculiar CD27 population expressing Fc receptor homologue 4 (FcHR4, now referred to
as FcRL4) was described in human tonsil, with comparable somatic mutation and activation
-

+

marker expression to classical tonsilar memory B cells (71). CD27 IgG populations were also
+

-

+

identified in the peripheral blood, comprising 25% of total IgG B cells (72); these CD27 IgG cells
+

phenotypically and morphologically resembled their CD27 counterparts, albeit with slightly
reduced somatic mutation frequencies and enrichment for the IgG3 isotype (72, 73). Subsequent
analyses of replication history and antibody maturation suggested associations between memory
+

+

-

+

B cell phenotype and origin: CD27 IgM and CD27 IgG likely derive from primary germinal center
+

+

+

+

reactions, while CD27 IgG and CD27 IgA cells develop from secondary reactions and CD27
+

+

-

-

IgA cells mature extrafollicularly (44). In another study, CD27 and CD27 class-switched
memory cells showed a genealogical relationship but CD27 expression was not specifically
associated with product or precursor cells (55). Together, these studies used evidence of somatic
hypermutation, clonal expansion, and/or specificity to previously encountered pathogens to
-

establish the existence of CD27 memory B cells.
+

The origin and identity of human IgM memory B cells, a population divided into
+

IgM IgD

low/-

+

+

(“IgM-only”) and IgM IgD subsets, remains a subject of debate. IgM-only cells
+

appear to be germinal center-derived and clonally related to class-switched CD27 memory B
+

+

cells (74). Conversely, IgM IgD cells were initially proposed to be either naïve cells with preimmune antibody mutations, TI response-derived cells, or the circulating counterpart of the
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splenic marginal zone B cell population (6, 74, 75). However, a number of studies identified
characteristics suggesting a germinal center-dependent origin for significant portions of the
+

+

+

IgM IgD pool, which molecularly, phenotypically, and functionally resemble IgG memory B cells
+

+

(6, 45). Taken together, IgM IgD memory B cells are likely a heterogeneous population with
multiple origins and biological niches.

Signals regulating memory B cell heterogeneity
The differentiation fate of activated naïve B cells (and potentially re-activated memory B
cells) is impacted directly by pathogen-derived molecular signals and cytokines produced by
various immune and non-immune cells in response to the infection (64, 76). Via this process,
specific infection cues shape the character of the subsequent antigen-specific memory B cell
response and ultimately generate a diverse pool of memory B cells. Murine studies indicate that B
+

cell differentiation can occur in a polarized way, analogous to CD4 T cell polarization, in a
process largely dependent upon cytokines: IFNg drives Th1-like differentiation in B cells, while IL4 drives Th2-like differentiation patterns (64, 77). These polarized B cells subsequently produce
signature cytokines associated with their respective immune response types, undergo specific
patterns of antibody isotype class switching, and are imprinted with a trafficking receptor profile
(65, 78, 79).
B cells further depend upon toll-like receptors (TLRs), innate sensors of pathogenassociated molecular patterns, to generate appropriate humoral responses. Naïve B cells only
express TLRs at low levels, but human memory B cells can express TLRs 1, 2, 6, 7, 9, and 10:
TLRs 1, 2, an 6 are plasma membrane-expressed and recognize bacterial antigens, while TLRs
7, and 9 are expressed in endosomes and recognize nucleic acids (TLR10’s function is unclear
(76)). TLRs are upregulated by cell activation and, by synergizing with BCR and CD40
stimulation, can further promote B cell activation and influence differentiation (80). TLR signaling
is critical at multiple stages of B cell development, as GC B cells are particularly sensitive to TLR
signaling and plasma cell differentiation directly depends on TLR activation (81-83). Deletion of
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TLRs or TLR-associated signaling molecules such as MyD88 in mice have been shown to
diminish the magnitude or quality of antibody responses against protein immunogens, viral-like
particles, and live replicating pathogens, directly demonstrating the impact of TLR-signaling on
developing humoral responses (76). Together, cytokine and TLR stimulation are transduced by a
number of signaling pathways that culminate in the activation of transcription factors to
subsequently alter gene expression.

Memory B cell migration and tissue distribution
Memory B cells utilize peripheral blood and the lymphatic system to traffic toward
lymphoid and non-lymphoid tissues where antigen encounter is most likely. Memory B cells have
been identified at mucosal sites, such as the gut and lungs, in the skin, in various lymphoid
tissues, and can be readily recruited to sites of inflammation (6, 84-86). The directed migration of
lymphocytes into tissues is dependent upon the processes of chemotaxis, the movement of cells
toward a chemokine gradient, and cell adhesion. Memory B cell subsets can be targeted toward
anatomical sites by expression of specific chemokine receptors and adhesion molecules; for
example, gut homing requires expression of the α4β7 integrin and the chemokine receptor CCR9,
whereas skin homing involves cutaneous lymphocyte antigen and contributions from chemokine
receptors CCR4, CCR6, and CCR10 under different conditions (84, 85).
Lymphocyte entrance into and exit from lymph nodes is perhaps the best described
trafficking process (87). B and T cells enter into lymph nodes via afferent lymph or from blood via
high endothelial venules (HEVs), and entry is highly dependent upon adhesion molecule
interactions: lymphocyte-expressed CD62L interacts with HEV-expressed addressins, causing
the cells to slow down, roll along the endothelial surface, engage endothelial ICAM1 and ICAM2
adhesion molecules via lymphocyte function-associated antigen 1, and extravasate between
endothelial cells into the lymph node parenchyma (87, 88). Chemokine receptors such as CXCR5
and CCR7 also support lymph node entry and further guide B cell localization within the lymph
node: CXCR5 signaling induces B cells and Tfh cells to traffic into B cell follicles, B cell-rich areas
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in which TD humoral responses are initiated and matured via the germinal center reaction (21,
22). T cell cortex surrounds these follicles, and CCR7 positions B cells near the T cell border to
facilitate B-T cell interactions (19). B cells leaving the lymph node emigrate into the lymphatic
system following a sphingosine 1-phosphate (S1P) gradient, from low concentrations in lymph
node parenchyma to high blood and lymph concentrations (89). Recent emigrants can travel to
and survey additional lymph nodes or enter the blood circulation via the thoracic or right lymphatic
ducts (90).
The spleen is a unique lymphoid organ optimized for blood-borne pathogen responses.
Spleen is comprised of two main compartments: white pulp, with a T cell zone and B cell follicles
that resembles lymph node structure, and red pulp, a macrophage-rich site that filters the blood
(91). In humans, follicles are surrounded by a two-layer marginal zone, which contains a specific
B cell subset termed marginal zone (MZ) B cells, and a perifollicular zone that further separates
the MZ and red pulp (91). Peripheral blood lymphocytes enter the spleen via splenic arterioles
that empty into the open circulation of the perifollicular zone, and these cells can subsequently
traffic into white pulp in a CCR7 or CXCR5-dependent manner or into the red pulp’s splenic
sinuses to exit the spleen along an S1P gradient (21, 22, 87, 91). Due to differences in structure
and cell composition between rodents and humans (i.e. lack of specific macrophage populations
in human splenic marginal zone), the mechanisms of blood sampling and antigen delivery to
human MZ B cells are unclear (92); however, MZ B cells are important for TI responses to bloodborne pathogens such as encapsulated bacteria and can quickly differentiate into plasmablasts
upon antigen encounter (6). Additionally, MZ B cells function to connect the innate and adaptive
immune systems by shuttling between the marginal zone and B cell follicles in an S1P-dependent
manner to deliver antigens for initiation of follicular responses (93). Unlike rodents, human MZ B
cells are somatically mutated and therefore represent a memory population (92). It is unclear if
human MZ B cells can traffic into the periphery or are spleen-restricted (6).
Since cell tracing is difficult in humans, it is often unclear whether B cells identified within
human peripheral tissues are transiently surveying for pathogens or reside permanently within
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these tissues. The concept of resident memory cells, specific subsets that remain in tissues and
do not re-circulate, is well described in the T cell literature but is poorly understood in the context
of B cells. To maintain tissue residence, T cells rely on integrins and other receptors to mediate
adhesion and actively inhibit egress mechanisms (94). Resident memory T cells (TRM)
characteristically express CD69, a C-type lectin that inhibits sphingosine 1-phosphate receptor 1
(S1P1)-regulated egress, and CD103 (αE integrin), which complexes with β7 integrin to mediate
epithelial cell adhesion (94, 95). While definitive B cell tissue residence markers have not been
defined, lymphocyte circulation studies in sheep indicate that specific subsets of B cells do not recirculate (i.e. are not found in lymph) and likely remain in tissues (96). Plasma cells generally do
not re-circulate and are resident in bone marrow and gut lamina propria (34, 35).

1.5 The transcription factor T-bet

T-bet in immunity
The T-box transcription factor family includes a number of genes critical for regulation of
developmental processes (97). Named after the Brachyury, or T gene, family members
characteristically contain a highly conserved, 180 amino acid T-box DNA binding domain (98). In
2000, Szabo et al. discovered a novel family member within T cells, which they termed T-bet (Tbox expressed in T cells (99)). T-bet was first described as a critical regulator of naïve CD4 T cell
differentiation into the T helper 1 (Th1) lineage, but subsequent studies have identified the
importance of this transcription factor in regulating development and effector functions of various
immune cell types, including CD8 T cells, NK cells, B cells, dendritic cells (DCs), and monocytes
(100). T-bet is expressed exclusively within the immune system where it promotes type 1 (Th1)
immunity against intracellular pathogens (100).
T-bet is critical for driving both innate and adaptive Th1 responses. Monocytes and DCs
are induced to express T-bet by IFNg stimulation, and DCs require this intrinsic T-bet expression
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+

to appropriately prime Th1 CD4 T cells and shape the subsequent adaptive immune response
(101, 102). Innate lymphoid cells, NK cells, invariant NKT cells, and γδ T cells, separate lineages
of innate-like lymphocytes, require T-bet at various developmental checkpoints and to drive
+

effector functions such as IFNg production (100). Th1 CD4 T cell development and IFNg
production also require intrinsic T-bet expression, and forced expression of T-bet in Th2 and
+

Th17 cells reverts these cells to a quasi-Th1 phenotype (99). CD4 T cells lacking T-bet cannot
mount Th1 responses and fail to control intracellular bacterial infections (99, 103). T-bet is also an
+

important regulator of CD8 T cell development and effector functions, although it works
cooperatively and often redundantly with the T-box family member Eomesodermin (Eomes (104,
105)). T-bet seems to be particularly important for early production of cytolytic proteins, such as
+

granzyme B, and IFNg, during CD8 T cell responses, and subsequent Eomes induction can
support and compliment these effector functions (100). Conversely, memory differentiation is
regulated differentially by T-bet and Eomes: T-bet promotes terminal differentiation into the
+

effector phenotype, while Eomes promotes the formation of central memory CD8 T cells (100).
Combined T cell receptor stimulation and signaling from inflammatory cytokines such as IFNg or
IL-12 promote T-bet expression in T cells (99, 106).
Mechanistically, T-bet functions both as a transcriptional activator to support Th1 identify
and a repressor to prevent the adoption of alternative lineage fates. T-bet actively promotes
expression of genes associated with the Th1 phenotype, such as Ifng and Cxcr3, and T-bet can
drive similar gene expression programs between different lineages by binding the same gene
targets in each cell type (107). However, T-bet also can promote separate lineage-specific Th1+

associated programs in different immune cells (e.g. cytolytic potential in CD8 T cells but not B
cells (100)). To support gene expression, T-bet recruits cofactors such as Runx3 for activation of
the Ifng gene and chromatin remodeling complexes to open target loci (108). For repression, Tbet similarly recruits Bcl-6, a transcriptional repressor, and exploits its repressive function to
silence specific non-Th1 genes (109). T-bet can also indirectly repress alternative lineage
development by binding to and inactivating GATA3 (Th2 differentiation) and Runx1 (activator of
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Rorc, which promotes Th17 differentiation (108)). These diverse gene regulation mechanisms
combine to support Th1 cell identity across the immune system.

T-bet in B cells
T-bet expression was first identified in mouse B cells by Glimcher et al., who found that
T-bet regulates IFNg production by B cells following Th1 cytokine (IL-12, IL-18) and CD40
stimulation (99). This B cell-produced IFNg was suggested to play an important
immunoregulatory role by promoting Th1 CD4 T cell development, and, in an analogous way,
autocrine Th1-type polarization of B cells (64) (65). However, subsequent studies identified
perhaps the most important B cell-specific function of T-bet: regulation of antibody isotype
switching to the IgG2a/c isotype (78) (110), the signature antibody isotype of humoral Th1-type
+

immune responses (111). Following completion of isotype switching, IgG2a memory B cells and
plasmablasts continue to depend on T-bet for their survival and functionality (112). Altogether, Tbet appears to function as a Th1 master regulator within the B cell compartment of mice by
+

controlling the early development of IgG2a B cells from naïve precursors and actively
+

maintaining the integrity of mature IgG2a memory B cells.
The roles of T-bet in regulating IFNg production and IgG2a class switching suggest that
this transcription factor primes B cells for antiviral responses. Early in vitro studies of cytokines or
other factors promoting B cell T-bet induction, such as IL-12, IL-18, and anti-CD40 stimulation,
have further supported this hypothesis (99). Subsequent studies have additionally identified IFNg
and IL-21 as potent inducers of T-bet expression and IgG2a isotype switching in B cells,
particularly when paired with TLR7 or TLR9 stimulation (78, 110, 113-116). As viral nucleic acids
can stimulate TLR7 and/or TLR9, and IFNg and IL-21 are produced by the immune system in
response to viral infections, these experiments suggested that viral infection would be ideal for
+

development of the T-bet B cell subset.
+

Despite this suggestive body of work, T-bet B cell involvement in specific antiviral
responses was not directly demonstrated until several years later. Using the gamma herpes virus
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+

68 mouse model of viral infection, Rubtsova et al. showed that T-bet B cells acutely expand,
produce anti-ghv68 antibodies, and are necessary to control viremia to low levels (117). More
recently, Barnett et al. (2016) used inducible B cell-specific T-bet knockout mice to show that T+

bet B cells are critical for maintaining control of chronic lymphocytic choriomeningitis infection,
through both virus-specific IgG2a production and antibody-independent functions (118). By
connecting viral loads to the presence of this population, these studies together have established
+

T-bet B cells as an antiviral subset, with a direct role in controlling multiple murine viral
infections.
In humans, T-bet expression has been identified in peripheral blood B cells specifically
within the context of inflammatory diseases, including systemic lupus erythematosus (SLE),
Crohn’s disease, multiple sclerosis, and chronic hepatits C virus (HCV) infection (119-122). In
lymphoid tissue, a subset of B cells termed monocytoid B cells normally express T-bet, and
widespread T-bet expression is detectable in B cells within Th1-type reactive lymphoid tissue
lesions and also several neoplastic lesions (123-125). T-bet’s induction in human B cells under
pathologic, inflammatory conditions raises the question of whether T-bet expression is aberrant or
a normal transcriptional regulator of human B cells.

1.6 B cells and HIV infection

HIV and immunopathogenesis
The first description of what would later be recognized as acquired immune deficiency
syndrome (AIDS) was made in 1981 with the observations of several homosexual men infected
with Pneumocystis carnii (126) and developing Kaposi’s sarcoma (127). The subsequent
identification of a novel retrovirus by multiple groups led to the characterization of the human
immunodeficiency virus (HIV (128)). HIV is a single-stranded RNA virus that binds to and enters
immune cells using CD4 and a co-receptor (commonly the chemokine receptors CCR5 or CXCR4
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+

(129)). HIV characteristically infects and kills CD4 T cells, leading to the significant loss of CD4

+

T cell numbers and progressive immunopathology culminating in AIDS and death (130). HIV
remains a global health crisis over 30 years after its initial discovery as the causative agent of
AIDS, with over 30 million individuals infected and nearly 2 million deaths per year attributed to
the infection (131). Attempts to create an HIV vaccine have largely failed due to the virus’
extraordinary antigenic diversity driven by high mutation and replication rates and its ability to
induce systemic immunopathology.
Following transmission and an eclipse phase when virus is undetectable in the blood,
+

excessive viral replication produces an acute peak in HIV viremia and concomitant loss of CD4 T
+

cells (132). This depletion results in diminished help to B cells and CD8 T cells, negatively
+

impacting the development of both humoral and cellular immunity to HIV (133). CD4 T cell
depletion in the GALT is particularly prevalent, and this process contributes to loss of mucosal
barrier integrity, microbial translocation, and subsequent systemic inflammation that further
impairs HIV immunity (134). Following peak viral load, HIV viremia is subsequently controlled to a
+

set point by CD8 T cell-dependent mechanisms (135). Since cellular and humoral immune
responses are unable to achieve viral clearance, most infected individuals maintain a steady state
+

of viremia asymptomatically for years until CD4 T cell numbers further decline and leave
individuals susceptible to opportunistic infections (133). HIV disease is characterized by chronic
viral replication and immune activation that impairs the functionality of all major immune subsets
(133).

The HIV Env antibody response
HIV infection elicits a strong humoral response against a number of viral proteins, with
antibodies targeting Env, the HIV surface glycoprotein, mediating the majority of antiviral effects.
IgM isotype antibodies emerge first during early acute HIV infection and recognize gp41, the
membrane bound Env subunit critical for mediating membrane fusion. These gp41 antibodies
subsequently undergo class switching to IgG and IgA but remain largely ineffective (136).
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Similarly, antibodies specific for a number of epitopes on gp120, the cap of Env that binds CD4
and co-receptors, begin to appear in a sequential manner approximately 4 weeks after infection
but rarely mediate neutralization (136-139). Autologous HIV neutralizing antibodies targeting Env
variable regions first appear 4-12 weeks after infection but are unable to neutralize current viral
quasispecies (54). A number of studies demonstrate that HIV Env-specific neutralizing antibodies
directly drive Env mutation, and some individuals mount early neutralizing responses that
significantly pressure the virus (137, 140); however, a situation develops in most chronically
infected individuals where the generation of Env sequence diversity greatly outpaces autologous
neutralization development, thereby preventing antibody-mediated clearance of HIV (54).
In recent years, technological advances have enabled the isolation and characterization
of multiple classes HIV broadly neutralizing antibodies (bNAbs (141)). Unlike typical Env-specific
antibodies, bNAbs demonstrate significant neutralizing capacity against diverse heterologous
viruses (142). These antibodies develop in a subset of chronically infected individuals only after
years of infection, suggesting their maturity requires prolonged viremia and/or immune activation
(143). These antibodies function by targeting sites of weakness on the Env protein, including the
CD4 binding site, membrane proximal external region, gp120-gp41 interface, and V1-V2 glycan,
and are further characterized by abnormal features such as long complementarity determining
region 3 (CDR3) regions, excessive somatic hypermutation levels, and increased autoreactivity
(143, 144). While bNAbs arise late in the course of infection and are unable to neutralize
concurrent dominant HIV variants in the infected individual, their development indicates that the
human body is capable of producing antibodies that can neutralize genetically diverse strains of
HIV.

B cell hyperactivity and subset alterations
From the earliest descriptions of HIV infection, B cell hyperactivity was evidenced in
viremic individuals by lymphadenopathy, hypergammaglobulinemia, and increased activation
marker expression, cell turnover, and cell death (145, 146). The B cell compartment is
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significantly impacted by HIV infection, demonstrating drastic alterations in cell phenotype,
functionality, and the representation of particular subsets (146). Many of these changes are due
to the effects of excessive infection-induced cytokines and viral replication products on B cells
and other immune cells that regulate B cell development (147). Hyperactivation and many of the
B cell subset imbalances can be normalized by lowering immune activation with antiretroviral
therapy (ART); however, ART-treated individuals exhibit instances of deficient humoral recall
responses and an incomplete restoration of resting memory B cell numbers by ART, suggesting
that chronic viremia irreversibly depletes a portion of humoral memory either directly or indirectly
+

through the loss of CD4 T cell help (146, 148). These HIV infection-induced perturbations may
impede the development and maintenance of protective B cell and antibody responses,
contributing to chronic persistence of the virus in untreated individuals. However, it is important to
note that HIV infection does elicit a strong and evolving humoral response that places
immunological pressure on the virus (137, 138).
The peripheral B cell compartment in HIV-infected individuals is significantly altered
-

compared to HIV individuals, with observable differences in the representation of nearly every
subset (147). Transitional B cells, recent immature bone marrow emigrants detectable at a low
+

frequency in healthy individuals, are increased in number as a result of CD4 T cell
lymphocytopenia and increased IL-7 levels (149). The inflammatory environment of HIV infection
is thought to drive polyclonal B cell activation and terminal differentiation and to promote memory
B cell apoptosis; as such, decreases in naïve and resting memory B cells and increased
plasmablast numbers are commonly observed (147). Viremic HIV infection is also associated with
the expansion of atypical memory B cells, subsets present at low to undetectable levels in healthy
individuals that can be identified by a loss of CD21 expression. These cells are commonly
-

+

-

-

subsetted and defined as activated (CD21 CD27 ) and tissue-like memory (CD21 CD27 ) B cells,
and the latter has been described as “exhausted” due to its low proliferative capacity following
BCR (150, 151).
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The B cell response to HIV
Many aspects of the HIV-specific B cell response are poorly understood, due to the historical lack
of cell identification technologies and the field’s general emphasis on studying antibodies (147).
Recently, HIV Env probes were developed to enable flow cytometric sorting of virus-specific
memory B cells for cloning of HIV-specific antibodies (152, 153). This process is commonly used
for the identification and characterization of bNAbs from infected individuals, but these probes
also afford the opportunity to assess characteristics of the HIV-specific memory B cell
compartment itself. Studies of HIV-specific B cells during acute infection are lacking since
individuals are rarely diagnosed before the chronic phase of infection, but HIV Env probe-based
work suggests much of the early gp41-focused IgM isotype antibody response is generated from
cross-reactive, commensal bacteria-specific B cells (154). Interestingly, analyses of chronically
infected individuals found that HIV-specific responses are concentrated in activated and tissuelike memory B cells instead of classical memory B cells, a phenomenon often interpreted to
reflect immune dysfunction (155). However, the detrimental impact of an atypical memory cellbiased (versus classical memory-biased) response has not been directly demonstrated, and the
mechanisms shifting HIV-specific B cell development into the atypical memory path are unclear.

1.7 Thesis goals

Complex viruses such as influenza and HIV have moved the vaccinology field from its empirical
roots into a new era of rational-based vaccine design requiring careful characterization of
protective immune correlates. To this end, identification of the mechanisms regulating human
antiviral B cell responses will provide biomarkers to assess the immunogenicity of vaccine
candidates and molecular targets for intervention to improve vaccine-induced immune responses.
Despite significant advances in antibody characterization, factors regulating antiviral humoral
immunity and the specific B cells mediating acute responses remain undefined. As such, the goal
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of this thesis was to better define the cells and mechanisms that promote humoral antiviral
responses by characterizing T-bet’s role in the human B cell compartment and assessing T-bet
B cells’ involvement in the HIV immune response
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CHAPTER 2
	
  
IDENTIFICATION AND CHARACTERIZATION OF HUMAN T-BET-EXPRESSING B
LYMPHOCYTES

2.1 Summary

Humoral immunity is critical for viral control, but the identity and mechanisms regulating human
antiviral B cells are unclear. Here, we characterized human B cells expressing the transcription
+

factor T-bet and analyzed their dynamics during live viral vaccinations. T-bet B cells, a relatively
small component of the peripheral B cell compartment in healthy individuals, demonstrated a
memory phenotype and were enriched for the antiviral immunoglobulin isotypes IgG1 and IgG3.
We identified T-bet

high

and T-bet

responses to vaccination: T-bet

low

high

B cell subsets with divergent phenotypic profiles and
cells were highly activated, transcriptionally distinct from

resting memory B cells and plasmablasts, and expanded acutely and transiently following yellow
fever and vaccinia virus vaccinations. Conversely, T-bet

low

cells displayed a resting phenotype

and were unresponsive to acute viral infection in most donors. T-bet

low

cells were readily

identified in peripheral blood, lymphoid tissues, and in thoracic duct fluid, while T-bet

high

cells were

found primarily in the peripheral blood and in low numbers within the spleen. Together, these
findings suggest T-bet regulates antiviral immunoglobulin isotype switching and development of a
distinct T-bet

high

B cell subset that is responsive to viral replication and/or inflammatory signals in

healthy individuals.
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2.2 Introduction

The humoral immune system is critical for control of multiple viruses during both acute and
chronic phases of infection (118, 156), and most effective vaccines are thought to function by
eliciting a protective humoral response (4). Humoral immunity is coordinated by memory B cells,
antigen-specific subsets that can regulate the developing immune response via functions such as
antigen presentation, cytokine production, or differentiation into antibody-secreting cells (62, 157,
158). Memory B cells can also express different antibody isotypes which fulfill diverse
spatiotemporal and pathogen-specific roles upon secretion (6, 52). Heterogeneity has been
demonstrated within the origins, development, and functional capacity of human memory B cell
populations differentiated by a variety of cell surface markers (6). Recent studies have begun to
assess the contributions of divergent B cell subsets during active immune responses using
antigen-specific probes (155, 159), but the identity and regulation of memory B cells responding
to active human viral infections remain poorly understood.
Recently, several studies have identified atypical memory B cells as bona fide antigenexperienced subsets (44, 55, 72, 73, 151). These cells differ from classical memory B cells by
their activated phenotype (151) and/or absence of CD27 expression (44, 55, 72, 73), a traditional
marker of B cell memory (68, 69), but show evidence of a germinal center origin based upon
antibody isotype switching and somatic hypermutation (44, 55, 72, 73, 151). Atypical memory B
cells have subsequently been described in the context of chronic inflammatory settings in which
they are abnormally expanded (73, 121, 151, 160-163), and their refractory response to normal B
cell receptor stimulation has led to the hypothesis that they are an anergic byproduct of excessive
inflammation (151, 162). However, the immunological role for these populations is unclear.
Transcription factors are critical regulators of memory B cell identity and function that can
translate pathogen-specific cues into induction of appropriate humoral responses (76, 112, 113,
164). Recent studies identified the immune cell-specific transcription factor T-bet as a critical
regulator of murine antiviral B cell responses (117, 118). T-bet was originally described to control
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+

CD4 Th1 cell development and functionality (99), but T-bet also plays a role in B cell
differentiation (64, 78). In mice, T-bet expression is required for isotype switching, functionality,
+

and survival of IgG2a/c memory B cells (78, 110, 112) and can also regulate the expression of
the antiviral cytokine IFNg and the inflammatory homing receptor CXCR3 in this population (65,
+

79). Several groups recently examined the direct role of T-bet B cells during murine viral
+

infections: gamma herpes virus 68 induces an expansion of T-bet B cells, the absence of which
leads to infection exacerbation (117). Similarly, chronic lymphochoriomeningitis (LCMV) viremia is
+

controlled to low levels only in the presence of T-bet B cells via a chiefly IgG2a-dependent
mechanism (118). B cells expressing either TBX21 transcript or T-bet protein have been
described in the context of autoimmune diseases, chronic hepatitis C infection, and malaria
infection (120, 121, 162, 165, 166), but the biological niche of this population in healthy humans
has not been defined.
In this study, we characterize the phenotypic and transcriptional profiles of human T-bet

+

+

B cells and examine their dynamics during acute human viral infections. We identified T-bet B
cells in healthy human peripheral blood as an antigen-experienced population that demonstrates
-

+

a potentially antiviral phenotype. Unlike T-bet memory B cells, a subset of T-bet B cells is
activated and transiently expands in response to acute viral infections. Our data identify T-bet
+

induction in the B cell compartment by human viruses and suggest that T-bet B cells participate
in the antiviral response.
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2.3 Results

2.3.1 Human peripheral blood B cells can express the Th1 transcription factor T-bet

Human T cells and NK cells express the Th1 transcription factors T-bet and Eomesodermin
(Eomes), which regulate cell differentiation and effector functions (100, 167-170). We set out to
identify B cells expressing these transcription factors in healthy individuals and to compare
expression levels to other peripheral blood mononuclear cells (Figure 1A). While a relatively low
+

+

frequency of B cells (~10%) expressed T-bet compared to CD4 T cells (~30%), CD8 T cells
(~65%), and NK cells (~100%), T-bet was consistently detected in B cells of all tested donors
(Figures 1B and 1C). T-bet expression levels (median fluorescence intensity, or MFI) within the T+

+

bet B cell subset were comparable to T-bet T cells, while NK cells demonstrated the greatest Tbet MFI (Figures 1B and 1D). Unlike T and NK cells, Eomes expression was not detected in B
+

cells (Figures 1E and 1F). Monocytes and CD11c dendritic cells did not express either T-bet or
Eomes (Figures 1B, 1C, 1E, 1F, and data not shown), suggesting Th1 transcription factors do not
regulate human myeloid cells at rest.
T-bet expression in T cells is restricted specifically to memory subsets (100). In order to
+

define T-bet B cell populations in human blood, we developed a panel to assess all major
peripheral B cell subsets through expression of CD10, CD38, CD27, CD21, and immunoglobulin
(Ig) D (Figure 2A). We found that significantly more memory B cells expressed T-bet compared to
transitional B cells, naïve B cells, and plasmablasts (Figures 2B and 2C). As T-bet is known to
regulate antibody class switching to IgG2a/c in mice (78, 110), we further assessed the
relationship between T-bet and human memory B cell BCR isotypes (Figure 2D). T-bet was
+

expressed at the highest frequency by IgG cells, specifically those expressing IgG1 or IgG3,
which are critical for antiviral responses ((52); Figure 2E). However, T-bet expression could also
be detected to a lesser degree in subsets of B cells expressing the other tested antibody isotypes
(Figure 2E).
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Figure 1: T-bet expression in peripheral blood lymphocytes and monocytes
(A) Gating scheme depicting the identification of major blood immune subsets in a healthy
-

+

-

-

-

+

+

+

individual; monocytes, CD3 CD14 CD19 ; B cells, CD3 CD14 CD19 ; CD4 T cells, CD3 CD14
-

+

-

+

+

-

-

-

+

-

-

-

CD19 CD4 CD8 ; CD8 T cells, CD3 CD14 CD19 CD4 CD8 ; NK cells, CD3 CD14 CD19 CD4
-

+

+

-

-

+

CD8 CD7 CD56 /CD16 . (B) Histogram depicting T-bet expression per subset from a
+

+

representative individual; CD4 T cells, blue; CD8 T cells, grey; NK cells, black; B cells, red;
monocytes, green. (C) Frequency of T-bet expression of each subset in an 8-donor cohort. (D) T+

bet MFI of T-bet cells per subset. (E) Histogram depicting Eomes expression of each subset
from a representative individual. (F) Frequency of Eomes expression per subset.
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Figure 2: T-bet expression in B cell subsets and by antibody isotype
(A) Representative gating scheme for the identification of B cell subsets named in red from the
+

+

peripheral blood of a healthy human donor. Trans., transitional, CD19 CD10 CD38
-

high

CD27

+

-

low

excluding the naïve (CD21 CD27 ) population. (B)

memory cells, CD19 CD10 CD38

+

-

; naïve, CD19 CD10 CD38
+

low

+

-

CD27 ; PBs,

+

plasmablasts, CD19 CD10 CD38

high

mid

-

+

CD21 CD27 IgD ; total

-

Representative flow cytometry plots of T-bet expression in peripheral blood B cell subsets from a
single donor. (C) T-bet expression frequency per subset in a 10-donor cohort. Bars on these and
all following plots represent mean ± standard error. (D) Representative identification of memory B
cell surface-expressed antibody (BCR) isotypes named in red. (E) T-bet expression frequency of
memory B cells expressing different antibody isotypes. Statistical comparisons in C and E
calculated using repeated measures one-way ANOVA with Tukey’s multiple comparisons test. **
denotes a P value 0.01 > P ≥ 0.001. *** denotes a P value < 0.001.
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2.3.2 Identification of T-bet

high

and T-bet

low

B cell subsets

+

To further define the characteristics of T-bet memory B cells, we used CD21 and CD27 to
-

delineate several previously described populations ((151); Figure 3A). The two CD21 subsets,
-

+

-

-

activated memory (AM, CD21 CD27 ) and tissue-like memory (TLM, CD21 CD27 ) B cells,
expressed T-bet at the highest frequencies (Figure 3B) and at significantly higher levels per cell
+

+

(Figure 3C) compared to resting memory (RM, CD21 CD27 ) cells, indicating a prominent role for
-

T-bet in regulation of the peripheral CD21 memory B cell compartment. Interestingly, we
identified a bimodal expression pattern of T-bet in AM and TLM subsets (Figure 3D); we therefore
-

+

explored additional cell surface receptors to better demarcate CD21 T-bet B cells and found that
-

this subset also highly expresses the inhibitory receptor CD85j (Figures 3E-G). The CD21 Tbet

high

CD85j

high

population (hereafter referred to as T-bet

high

CD85j

high

cells) was comprised of

approximately half the TLM population and nearly all of the AM population, whereas the
-

remaining TLM cells represent the CD21 CD85j

low

population (Figures 3H and 3I). In summary,

+

we identified two populations of T-bet B cells: a RM subset expressing T-bet at low levels (Tbet

low

cells) and a subset distinguished by a lack of CD21 expression and high levels of CD85j

that represents the main T-bet

high

B cell population in the peripheral blood of healthy human

donors.

2.3.3 T-bet

high

CD85j

high

B cells represent a transcriptionally and phenotypically distinct

memory subset

Seeking to better define this novel subset, we next investigated the transcriptional environment of
T-bet

high

B cells, using the CD85j

high

phenotype as a surrogate marker for Fluidigm Biomark

quantitative RNA analysis. Figure 4A depicts transcript expression levels of 91 selected target
genes, including transcription factors, activation and inhibitory receptors, trafficking receptors, cell
survival/death proteins, and other B cell-relevant genes within sorted B cell subsets from four
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Figure 3: T-bet expression in peripheral blood memory B cell subsets
low

-

(A) CD21/CD27-based gating scheme of total CD38 CD10 B cells from a representative donor;
+

-

+

+

activating memory, AM, CD27 CD21 ; resting memory, RM, CD27 CD21 ; tissue-like memory,
-

-

TLM, CD27 CD21 . (B) T-bet expression frequency of CD21/CD27-derived B cell subsets. (C) T+

bet median fluorescence intensity (MFI) of T-bet cells from each B cell subset. (D) AM (blue) and
TLM (black) T-bet expression histogram from a representative donor. (E) Gating of CD21
CD85j

high

-

and CD21 CD85j

low

-

low

-

B cell subsets from a representative donor’s total CD38 CD10 B

cells. (F) T-bet expression histogram of CD85j-gated B cell subsets from donor depicted in E. (G)
T-bet expression frequency of CD85j-gated B cell subsets in 10-donor cohort. (H) Flow cytometry
plots depicting the gating of AM and TLM into CD85j

high

and CD85j

low

populations. Total B cells

are depicted in black contour plot; TLM/AM subsets are depicted in blue dot plot. (I) Frequency of
AM and TLM subsets demonstrating the CD85j high phenotype (n=10 donors). Statistical
comparisons in B and C calculated using repeated measures one-way ANOVA with Tukey’s
multiple comparisons test. Statistical comparison in G calculated using paired t-test. *** denotes a
P value < 0.001.
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healthy donors. Unbiased clustering analysis of gene expression data demonstrated consistent
clustering of B cell subsets between donors, indicating our chosen panel clearly differentiates
peripheral B cell populations (Figure 4A). T-bet

high

CD85j

high

cells’ transcriptional signature

included highest expression of the antibody class switching and somatic hypermutation enzyme
AICDA, the glycosylation enzyme B4GALT3, transcription factors IKZF1 (Ikaros) and SOX5, the
inhibitory receptor SIGLEC6, and, importantly, TBX21 (T-bet) (Figure 4A). CD85j high cells
shared high expression of CCR6, FCRL3, FCRL4, NFIL3, PBX4, and TNF with RM cells, FCRL5
and TOX2 with plasmablasts, and BATF, CASP3, CD27, FAS, FUCA2, FUT8, and POU2AF1
with both populations (Figure 4A).
To interrogate transcriptional similarity between T-bet

high

CD85j

high

cells and the other

sorted B cell subsets in an unbiased way, we performed t-distributed stochastic neighbor
embedding (tSNE) analysis of the transcript expression results (Figure 4B). T-bet

high

CD85j

high

cells were transcriptionally dissimilar to antigen-inexperienced B cells and clustered near to, but
distinct from, resting memory B cells and plasmablasts, further suggesting this is an antigen-

-

experienced population. Interestingly, CD85j low B cells, the CD21 T-bet counterpart of our cells
of interest, were more similar to the antigen-inexperienced subsets (naïve, transitional; Figure
4B), suggesting these are relatively unrelated to T-bet

high

CD85j

high

cells and confirming the
-

-

previously described population heterogeneity within the TLM phenotype (CD21 CD27 ; (171)).
We further assessed phenotypes of T-bet

high

CD85j

high

cells at the protein level and found

this subset also highly expressed several homing receptors, activation markers, additional
inhibitory receptors (Figure 4C), and demonstrated a diverse repertoire of antibody isotypes
(Figure 4D). Interestingly, T-bet

high

CD85j

high

cells highly expressed the transcription factor

irrespective of surface Ig isotype expression (Figure 4E), suggesting additional Ig isotypeindependent roles for T-bet in this population. Taken together, comparative transcriptional and
phenotypic studies identify T-bet

high

CD85j

high

cells as a highly activated, antigen-experienced

population characterized by distinctive homing receptor and transcriptional profiles.
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Figure 4: Transcriptional and phenotypic analyses of T-bet

high

CD85j

high

cells and other B

cell subsets
(A) Heat map depicting relative RNA transcript expression levels for 91 targets (one per row) in
HIV-negative donors (n=4). Each column represents a specific B cell subset (colored bars above
and below heat map) sorted from one donor. (B) tSNE analysis of transcriptional relationships
between sorted B cell subsets from four healthy donors. Each color represents a sorted B cell
subset and clusters are highlighted with the corresponding color. (C) Expression frequency of
homing receptors (CD11c, CXCR3), activation markers (CD69, CD71, CD86, CD95), and
inhibitory receptors (PD-1, FcRL4/5) by CD38
isotypes expressed by T-bet
bet

high

CD85j

high

high

CD85j

high

low

cells (n=10). (E) T-bet expression frequency of T-

cells separated by Ig isotype (n=10). Statistical comparisons in C and E
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-

CD10 B cell subsets. (D) Frequency of antibody

calculated using repeated measures one-way ANOVA with Tukey’s multiple comparisons test. No
statistical differences were observed between isotypes in E. Statistical comparison in I calculated
using paired t-test. * denotes a P value 0.05 > P ≥ 0.01. ** denotes a P value 0.01 > P ≥ 0.001.
*** denotes a P value < 0.001.
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2.3.4 Divergent circulatory patterns between T-bet

high

We hypothesized that the differing phenotypes of T-bet

and T-bet

high

low

and T-bet

low

B cells

B cells would impact their

migratory capacity. To understand the circulatory potential of these subsets, we compared the
composition of B cell compartments in peripheral blood (PBMC) to the thoracic duct (TD), the
body’s largest lymphatic vessel that collects lymph draining from both lymphoid and non-lymphoid
tissues and empties into the blood (90). We isolated mononuclear cells from paired peripheral
blood and thoracic duct fluid (chyle) samples obtained from adults undergoing interventional
surgery (see Methods). Compared to PBMC, TD generally lacked myeloid cells and was
comprised mainly of T cells, B cells, and a small number of NK cells (data not shown). We
assessed the main B cell subset phenotypes found in healthy human blood (Figure 2A) and
identified the presence of transitional, naïve, memory, and plasmablast populations in TD of all
donors (Figure 5A). Transitional B cell and plasmablast frequencies were similar between PBMC
and TD compartments (data not shown), while memory B cells were underrepresented in TD
compared to PBMC and naïve cells were more frequent in TD (Figure 5B). Overall, the B cell
compartment within these two anatomical sites was similar.
We next investigated T-bet expression by TD B cells and consistently identified
+

diminished frequencies of total T-bet memory B cells in TD compared to PBMC (Figures 5C and
+

10D), suggesting some T-bet B cell subsets may not migrate through the thoracic duct. To
understand this phenomenon, we examined T-bet

high

-

cells (CD21 T-bet

high

CD85j

high

phenotype;

see Figures 3E and 3F) and found that this subset was virtually absent from the TD B cell
compartment, despite detectable T-bet

high

(Figures 5E and 5F). Conversely, T-bet

low

cell frequencies in PBMC of all matched donors
cells, which could be readily identified within the CD21

population by CXCR3 expression (Figures 5G and 5H), were present at comparable frequencies
in both PBMC and TD (Figure 5I). These findings suggest differential circulatory capacities of Tbet

high

and T-bet

low

low

+

cells: T-bet CXCR3 cells migrate through the thoracic duct and are able to

re-circulate back into blood, while T-bet

high

cells rarely enter into lymph.
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+

Figure 5: B cell subset distribution and T-bet expression in paired peripheral blood and
thoracic duct samples
(A) Gating scheme depicting identification of major B cell subsets as defined in Figure 2A from a
representative donor’s peripheral blood (PBMC) and thoracic duct fluid (TD). (B) Frequency of
naïve (black) and total memory (blue) B cells in 8-donor cohort. (C) Representative flow
cytometry plots of T-bet expression in total memory B cells from a representative donor’s PBMC
and TD. (D) T-bet expression frequency in total memory B cells from PBMC and TD in 8-donor
cohort. (E) Identification of T-bet

high

CD85j

high

subset within total B cells from a representative

donor’s PBMC and TD. (F) Frequency of T-bet

high

CD85j

+

high

subset within total B cells in 8-donor

-

+

+

cohort. (G) Identification of CXCR3 (blue) and CXCR3 (red) subsets within RM (CD21 CD27 )
+

population of PBMC and TD. (H) T-bet expression histograms of CXCR3 (blue) and CXCR3
low

-

+

(red) subsets from G in PBMC and TD. (I) Frequency of T-bet CXCR3 subset within total B
cells in 8-donor cohort. Statistical comparisons in B, D, F, and I calculated using paired t-test. **
denotes a P value 0.01 > P ≥ 0.001.
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2.3.5 Human spleen harbors a large T-bet-expressing B cell population

Having identified diverse circulatory patterns, we next investigated the tissue distribution of T-bet

+

B cell subsets. We assessed T-bet expression in B cells obtained from different lymphoid tissues,
including iliac lymph nodes (iLN), mesenteric lymph nodes (mLN), tonsils, and spleens that were
acquired following surgery (Figure 6A). Iliac lymph node, mesenteric lymph node, and tonsil B
cells expressed T-bet at a similar, albeit reduced, frequency compared to PBMC B cells (Figures
+

6A and 6B); however, MFI of the T-bet population in each case was significantly lower than that
of PBMC B cells (Figure 6C). To determine the types of lymphoid tissue B cells expressing T-bet,
we examined major lymph node B cell subsets and identified six donor samples for analysis (two
mLN, four tonsil) in which each of the lymphoid populations was sufficiently represented (Figure
6D). T-bet was not characteristically expressed by any specific lymphoid tissue B cell subset, and
low T-bet MFI made detection difficult (Figure 6E); however, germinal center B cells (GC;
CD38

mid

+

+

+

+

+

Bcl-6 CD10 Ki67 CD21 ) and CD27 memory B cells exhibited increased T-bet MFI

compared to naïve and germinal center-like (GC-like; CD38

mid

-

+

+

-

Bcl-6 CD10 Ki67 CD21 ) B cells

(Figures 6E and 6F). Notably, T-bet expression in lymphoid tissues did not associate with
diminished CD21 expression as it does in PBMC (Figure 3). In summary, T-bet is expressed only
at low levels (frequency and MFI) in iLN, mLN, and tonsil in the absence of an apparent, active
+

immune response, specifically in the GC and CD27 memory subsets.
The spleen is a physiologically distinct lymphoid organ comprised of a white pulp region
bearing similarities to lymph nodes and a red pulp region in which macrophages directly sample
the blood for antigens (91). The spleen’s B cell compartment also differed significantly from the
other assessed lymphoid organs, as spleen samples contained a large memory B cell population
but few GC or GC-like B cells (data not shown). Interestingly, splenic B cells expressed T-bet at a
significantly higher frequency and MFI than PBMC, iLN, mLN, and tonsil B cells (Figures 6A, 6B,
+

and 6C), suggesting the spleen may characteristically harbor a large T-bet B cell population.
+

-

These T-bet B cells were comprised of two distinct subsets: a small CD21 T-bet
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high

CD85j

high

B

Figure 6: T-bet expression in iliac lymph nodes, mesenteric lymph nodes, tonsil, and
spleen
(A) Flow plots depicting representative T-bet expression in total B cells from various unpaired
lymphoid tissues; peripheral blood, PBMC; iliac lymph node, iLN; mesenteric lymph node, mLN.
(B) Frequency of T-bet expression per lymphoid tissue B cell population; 6 PBMC, 6 iLN, 6 mLN,
+

4 tonsil, 6 spleen samples. (C) T-bet MFI of the T-bet B cells from each lymphoid tissue. (D)
Identification of lymph node subsets in a representative mLN, with subsets named in red;
germinal center B cells, GC, CD38
like, CD38
CD38

low

mid

-

+

mid

+

-

low

-

+

+

+

+

Bcl-6 CD10 Ki67 CD21 ; germinal center-like B cells, GC-

Bcl-6 CD10 Ki67 CD21 ; plasmablasts, PB, CD38
+

high

+

; CD27 memory,

+

CD27 ; naïve, CD38 CD27 CD21 . (E) T-bet histogram of lymph node subsets from a
+

representative mLN; naïve, grey; GC-like, blue; GC, red; CD27 memory, black. (F) T-bet MFI of
+

+

lymph node subsets in 6-donor cohort (2 mLN, 4 tonsil). (G) Identification of CD21 T-bet and
-

+

CD21 T-bet subsets in PBMC and spleen of two representative donors. (H) Identification of
+

CD21 spenic subsets named in red from a representative donor. (I) T-bet expression frequency
+

of splenic CD21 subsets in 6 donor cohort split into two groups: donors with high (>40%; blue)
and low (<40%; black) total frequencies of T-bet expression in the spleen in (see Figure 6B).
Statistical comparisons in B, C, and F calculated using one-way ANOVA with Tukey’s multiple
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comparisons test. * denotes a P value 0.05 > P ≥ 0.01; ** denotes a P value 0.01 > P ≥ 0.001. ***
denotes a P value < 0.001.
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cell population that phenotypically resembled its PBMC counterpart (Figure 6G), and a large
+

+

+

+

CD21 T-bet B cell population that dwarfed the PBMC CD21 T-bet subset in size and accounted
+

for the majority of T-bet B cells in spleen (Figure 6G).
+

+

To better define splenic CD21 T-bet B cells, we investigated the association between T+

bet and diverse phenotypes within the CD21 population (Figure 6H). T-bet was detected in all
+

-

+

+

CD21 memory subsets examined, including isotype switched (IgM ), unswitched (IgM ), CD27 ,
-

+

-

and CD27 populations, with CD27 IgM memory B cells expressing T-bet at the highest
frequency (Figure 6I). We also observed T-bet expression by phenotypically naïve B cells
+

-

+

(CD21 CD27 IgD ), suggesting T-bet induction may precede the development of a memory B cell
+

phenotype in this tissue (Figure 6I). Interestingly, individuals with particularly high T-bet splenic B
+

cell frequencies (>40% T-bet ; Figure 6B) did not exhibit expansion of a particular T-bet+

+

expressing subset; instead, they maintained a phenotypically diverse splenic CD21 T-bet B cell
pool with elevated T-bet expression frequencies across all subsets (Figure 6I). Together, these
+

findings suggest human spleen represents a reservoir for members of the T-bet B cell
population.

+

2.3.6 T-bet B cells are induced during acute viral infections

	
  
+

T-bet B cells have previously been shown to expand during acute LCMV and ghv68 infections in
+

mice (117, 118); we therefore asked whether human T-bet B cells might similarly be induced
during human acute viral infections. To assess this, we examined B cell responses in yellow fever
(YFV) and vaccinia (VV) virus vaccinated human subjects. These replicating live virus vaccines
are thought to elicit durable protection via antibody-mediated mechanisms (4, 172-174),
suggesting a critical role for B cells in this process. We analyzed T-bet expression within total
memory B cells collected from the peripheral blood of vaccinated individuals on the day of
vaccination, at weekly acute time points, and at a final time point ranging from 2 to 8 months post+

vaccination (Table 1). We identified the emergence of a T-bet population as early as two weeks
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Vaccinia

Yellow
Fever

Donor
ID
12
13
501
502
503
507
548

Week
0
Pre
Pre
Pre
Pre
Pre
Pre
Pre

Week
1
7
7
7
7
7
7
7

Week
2
14
17
15
14
14
14
14

Week
3
21
21
22
23
21
21
21

Week
4
28
28
29
28
28
29
28

Week
25+
180
184
183
183
181
195
271

Donor
ID
4
12
558
559
565

Week
0
Pre
Pre
1
1
1

Week
1
8
n/a
n/a
8
9

Week
2
15
14
15
15
16

Week
3
20
22
22
22
23

Week
4
28
30
29
32
30

Week 8+
184
203
218
120
60

Table 1: Yellow fever virus and vaccinia virus vaccine recipients. Blood sample timing for
n=7 vaccinia virus vaccine recipients and n=5 yellow fever vaccine recipients are depicted in
Table 1. Each row represents one donor with longitudinal samples collected at each day post
vaccination. Columns show binning of sampling into weeks post vaccination.
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post-YFV and VV vaccinations, which expanded and remained detectable in peripheral blood
+

through week four post-vaccination (Figures 7A and 7B). The frequency of total T-bet B cells
peaked around week four in the majority of individuals receiving either YFV (Figure 7C) or VV
+

(Figure 7D) vaccination, suggesting that both vaccines stimulated a T-bet B cell response. The
T-bet

high

CD85j

high

B cell frequency also peaked at week four in YFV-vaccinated individuals (Figure

7E), and expansion was preceded by expression of the activation marker Ki67 in this population
at week two post vaccination (Figure 7F). While T-bet

high

CD85j

high

cell expansion was not

detected in all donors during VV vaccination (Figure 7G), T-bet MFI in T-bet

high

CD85j

high

cells was

dynamic and peaked between weeks three and four during both YFV and VV responses (Figures
7H and 7I, blue lines). These responses were not limited to a single surface Ig isotype, as T-bet
+

expression increased in both IgM and class-switched T-bet

high

CD85j

high

cells (Figures 7J and

7K). Resting memory B cells (RM), which normally express low levels of T-bet (Figure 3B),
displayed increased T-bet expression frequencies in several VV vaccine recipients (Figure 7M)
but only in one YFV vaccine recipient (Figure 7L). This RM T-bet response involved only a small
subset of cells, as RM population size did not increase (data not shown) and T-bet MFI in the
total population remained static during both vaccinations (Figures 7H and 7I, black lines).
Interestingly, T-bet levels in plasmablasts also increased following each vaccination (Figures 7N
and 7O). Together, these findings indicate that human live viral vaccinations stimulate an acute T+

bet B cell response and that the T-bet

high

CD85j

high

during acute viral infections.
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population may function as an early-responder

+

Figure 7: Longitudinal T-bet B cell dynamics in yellow fever virus-vaccinated or vaccinia
virus-vaccinated individuals
Longitudinal T-bet expression in memory B cells of (A) a yellow fever (YFV) vaccinee and (B) a
vaccinia (VV) vaccinee. Time of blood sampling post-vaccination is depicted. (C) T-bet
expression frequency in total memory B cells of YFV vaccinees (n=5 for all YFV plots except F).
Donor samples were binned to organize approximate weekly time points. (D) T-bet expression
frequency of memory B cells in VV vaccinees (n=7 for all VV plots). (E) T-bet

high

CD85j

high

cell

frequency of total memory B cells in YFV vaccinees. (F) Ki67 expression frequency of Tbet

high

CD85j

high

cells in YFV vaccines (n=4). (G) T-bet

B cells in VV vaccinees. (H) T-bet MFI of T-bet

high

high

CD85j

CD85j

high

high

cell frequency of total memory

cells (blue) and resting memory (RM)

cells (black) in YFV vaccinees. No statistical differences were observed between RM time points.
(I) T-bet MFI of T-bet

high

CD85j

high

cells (blue) and resting memory (RM) cells (black) from VV
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vaccinnees. No statistical differences were observed between RM time points. T-bet MFI of Tbet

high

CD85j

high

+

cells separated by IgM expression is depicted in (J) for YFV and (K) for VV; IgM ,

-

black; IgM grey. Frequencies of RM cells expressing T-bet during YFV (L) and VV (M) responses
are shown. No significant differences were observed in L between time points. (N) T-bet MFI of
plasmablasts following YFV vaccination. (O) T-bet MFI of plasmablasts following VV vaccination.
Statistical comparisons in C, D, E, F, G, H, I, L, M, N and O calculated using repeated measures
one-way ANOVA with Tukey’s multiple comparisons test. * denotes a P value 0.05 > P ≥ 0.01. **
denotes a P value 0.01 > P ≥ 0.001.
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2.4 Discussion

The nature of the acute B cell response to human viruses remains poorly defined. To address this
issue, we assessed the phenotype and dynamics of B cells expressing T-bet, a known regulator
of Th1-type immunity across cell lineages, at rest and during acute human viral infections. We
+

identified T-bet B cells in the peripheral blood memory compartment of healthy individuals and
found an enrichment of antiviral antibody isotypes in this population. We further characterized Tbet

low

and T-bet

high

B cell subsets, the latter of which represents a distinct antigen-experienced

population with an activated phenotype. These subsets further displayed disparate tissue
localization profiles, as T-bet

low

B cells were found in peripheral blood, thoracic duct fluid, and

various lymphoid tissues, while T-bet

high

B cells were restricted to the blood and spleen. B cell T-

bet expression frequencies transiently increased in the blood in response to acute YFV and VV
infections, a phenomenon attributable to T-bet induction across multiple B cell subsets and the
specific activation and expansion of T-bet

high

CD85j

high

cells.

T-bet is considered to function as a master regulator of Th1-type immunity (100), and Tbet is known to promote antiviral B cell responses by driving IgG2a/c class-switching in mice (78,
110, 117, 118). Our findings suggest T-bet similarly regulates human B cells during acute Th1
immune responses, as we clearly demonstrate viral infection-induced T-bet expression in multiple
human B cell subsets. Our results further suggest antibody isotype diversification as a key effect
of this T-bet induction, as T-bet associates with the IgG1 and IgG3 isotypes in healthy individuals.
+

+

However, we also observed activation of the T-bet IgM population in response to acute YFV and
+

VV infections; further experiments are necessary to determine if these IgM memory cells are
particularly prone to IgG1 or IgG3 isotype switching, but this observation suggests additional
antibody isotype-independent roles for T-bet in human B cells. T-bet may influence additional
antibodies properties, as T-bet

high

CD85j

high

cells demonstrate elevated RNA transcript levels of

B4GALT3, a galactosyltransferase that may alter antibody glycosylation (36), and AICDA, the
enzyme critical for somatic hypermutation that leads to improved antibody affinity (37). T-bet may
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also influence antibody-independent functions and properties: similar to mice (79, 117), T-bet
likely regulates the expression of homing receptors CXCR3 and CD11c in human B cells,
+

potentially granting specific tissue and inflammation homing properties to T-bet cells. Murine
+

studies further suggest T-bet B cells in the spleen efficiently present antigen (63) and can be
stimulated to produce the cytokine IFNγ (65).
Our study identified a heterogeneous T-bet-expressing B cell population in human blood
comprised of two main subsets: T-bet
+

+

high

CD85j

high

low

expressing RM cells (CD21 CD27 T-bet ). T-bet

-

cells (CD21 T-bet
high

CD85j

high

high

CD85j

high

) and T-bet-

cells expand in response to acute

human viral infections (YFV and VV vaccinations) and closely resemble age-associated B cells, a
+

T-bet population in mice that accumulates with age, produces pathogenic autoantibodies, and is
critical for murine antiviral responses (114, 115, 117, 118). In contrast to T-bet
we did not observe significant expansion or activation of T-bet

low

high

CD85j

high

cells,

cells in most individuals

following YFV or VV vaccination, suggesting this subset does not play an active role during acute
antiviral B cell responses. While the origin and functions of T-bet
may represent quiescent descendants of T-bet

high

CD85j

high

low

cells remain unclear, they

cells that maintain long-lived antiviral

memory, as acutely-activated virus-specific B cell clones have been shown to seed the RM
population following resolution of acute infection (159).
We further identified differential circulatory abilities and tissue distributions of T-bet
and T-bet

low

cells. The T-bet

peripheral blood T-bet

low

low

high

population was found in all assessed tissues, suggesting

cells can enter into lymphoid organs, exit via the efferent lymph, and

travel to other lymphoid tissues or back into the blood via the thoracic duct. It is unclear whether
these cells remain in lymphoid tissue for extended periods of time or pass through transiently.
Conversely, we identified T-bet

high

cells in peripheral blood and the spleen but could not detect

them in lymph nodes, tonsil, or thoracic duct fluid, suggesting T-bet

high

cells do not traffic into

lymph nodes and do not egress from tissues in the absence of an immune response. The
+

+

relationship between splenic CD21 T-bet cells and the peripheral T-bet
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high

and T-bet

low

subsets is

+

+

unclear, but the sheer size of the splenic CD21 T-bet population suggests portions of these cells
are spleen-resident.
In summary, our study identifies T-bet

high

B cells as a novel viral infection-responsive

subset and suggests T-bet as an important mechanism regulating humoral antiviral immunity in
humans. T-bet

high

B cells’ rapid expansion during acute viral infections is reminiscent of effector T

cells and suggests they participate in the immune response by generating IgG1 and IgG3 isotype
antibodies and homing to sites of inflammation. In combination with T-bet

high

B cells’

responsiveness to viral infection, the previously reported outgrowth of T-bet-expressing B cells
during inflammatory conditions (120, 121, 162, 165, 166) suggests this population may be broadly
sensitive to inflammatory signals. Future studies should assess the direct contribution of T-bet
B cells to antigen-specific responses and investigate relationships between disparate T-bet
+

high

+

tissue B cell subsets to fully define the human T-bet B cell compartment’s immunological niche.
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CHAPTER 3
	
  
T-BET-EXPRESSING B LYMPHOCYTES ARE INDUCED BY HIV INFECTION AND
DOMINATE THE GP140-SPECIFIC B CELL RESPONSE

3.1 Summary

Current HIV vaccine efforts seek to induce protective antibodies, but the development and
regulation of the B cell response to HIV remain poorly understood. Here, we assessed the role of
T-bet-expressing B cells, a population critical for murine antiviral responses, during HIV infection.
+

T-bet B cells expanded during early acute HIV infection, were maintained at excessive levels in
chronic viremic infection, and associated with increased serum and cell-associated IgG1 and
IgG3 expression. Viral control was associated with contracting frequencies of T-bet
T-bet

low

high

B cells, but

B cells remained expanded in many aviremic donors. siRNA knockdown studies further

suggested a role for T-bet in the regulation of activation-induced cytidine deaminase RNA
expression. The HIV gp140-specific B cell response was dominated by T-bet-expressing memory
B cells, and we observed a concomitant biasing of gp140-specific serum immunoglobulin to the
IgG1 isotype. These findings suggest sustained T-bet induction by HIV infection alters the isotype
+

landscape of the B cell compartment and drives expansion and maintenance of a large T-bet B
cell population that coordinates the HIV Env-specific humoral response.
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3.2 Introduction

The HIV pandemic persists as one of the most significant global health problems (131). While
antiretroviral therapy has greatly improved mortality rates, a preventative vaccine remains
necessary to curtail the spread of HIV (175). Efforts have shifted to rational-based vaccine
design, requiring an in-depth analysis of immune responses to identify and stimulate protective
immunological correlates (144). Recent isolation and characterization of many naturally occurring
HIV-specific broadly neutralizing antibodies demonstrates the capacity of humans to generate a
potentially protective humoral response (176), but the B cells and mechanisms regulating
humoral immunity to HIV remain poorly characterized. An improved understanding of the B cell
response will identify interventional targets and inform rational vaccine design for HIV and other
viruses for which broadly effective vaccines do not exist.
HIV infection is characterized by excessive viral replication and inflammation that induce
a strong virus-specific humoral response and promote polyclonal B cell stimulation (54, 147). This
B cell hyperactivation likely contributes to previously described B cell subset alterations in
chronically infected individuals (147). The memory B cell compartment is particularly impacted by
HIV, with decreased resting memory B cell numbers and an expansion of activated and atypical
memory B cells that lack expression of the complement receptor CD21 (150, 151). It was
-

previously demonstrated that HIV-specific responses are over-represented in CD21 memory B
cells in viremic individuals (155), but the factors regulating HIV-specific B cells are unclear.
B cells expressing the transcription factor T-bet, a broad regulator of Th1-type immune
responses, are critical for controlling murine chronic viral infections (117, 118). We recently
identified T-bet-expressing B cells in human peripheral blood that are enriched for IgG1 and IgG3,
two antibody isotypes that efficiently mediate antiviral effector functions (Chapter 2). T-bet

high

cells, a subset of this population, are highly activated and transiently expand in response to
+

vaccination with diverse replicating viruses. These properties suggest T-bet B cells participate in
human antiviral responses, but their role during HIV infection is unknown.
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In this study we examine HIV-induced T-bet expression in B cells, the consequences of
+

this induction, and the involvement of T-bet B cells in the HIV immune response. We identified
+

rapid activation and expansion of T-bet B cells and increased T-bet expression levels in
plasmablasts during early acute HIV infection. Following the resolution of acute infection, the T+

bet memory B cell population was maintained at a high frequency into chronic HIV infection and
+

correlated with increased expression and secretion of IgG1 and IgG3 antibodies. This T-bet B
cell population maintains the anti-gp140 B cell response and, via the expression of T-bet, likely
+

biases gp140-specific antibodies to the IgG1 isotype. Our data identify T-bet B cells as
responders during both acute and chronic HIV infection and suggest this population orchestrates
the humoral immune response to HIV.

3.3 Results

+

3.3.1 Acute HIV infection induces T-bet B cell population expansion

	
  
In our previous study (Chapter 2) we assessed B cell dynamics during YFV and VV vaccinations,
which represent relatively controlled, low inflammation infections. We therefore investigated
+

whether T-bet B cells similarly expand during acute HIV infection, which is characterized by
excessive inflammation and immune pathology. To assess this, we obtained longitudinal
peripheral blood mononuclear cell samples from high-risk HIV seronegative individuals who
subsequently became infected with HIV from the U.S. Military HIV Research Program RV217
early capture HIV cohort (177). We analyzed T-bet expression in total memory B cells (Figure 2A)
from pre-infection, early acute, and early chronic infection time points (Table 2). During early
acute infection (days 1-21 after first positive HIV RNA test), six out of seven individuals
demonstrated a rapid increase in the frequency of T-bet-expressing memory B cells, supporting
the role of these cells as part of an early antiviral response (Figure 8A and 8B). Similar to YFV
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+

Figure 8: Longitudinal T-bet B cell dynamics in acutely HIV-infected individuals
(A) T-bet expression in memory B cells of an acutely HIV-infected individual before infection and
shortly after peak of viremia. (B) Memory B cell T-bet expression frequency from 7-donor cohort
of acutely HIV-infected individuals at pre-infection, acute, and chronic infection time points. (C) Tbet MFI of plasmablasts at pre-infection, acute, and chronic infection time points. Note that
intracellular T-bet staining for these samples was performed using BD Cytofix/Cytoperm Kit (Cat.
# 554722). Statistical comparisons in B and C calculated using repeated measures one-way
ANOVA with Tukey’s multiple comparisons test. * denotes a P value 0.05 > P ≥ 0.01. ** denotes a
P value 0.01 > P ≥ 0.001.
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Day relative
to first pos.
test
-194
21

VL
(copies/ml)
n/a
10965

CD4 count
(cells/ul)
n/a
775

30507

407
-289
17

17783
n/a
1122

446
n/a
1574

40067

413
-467
1

7585
n/a
229087

n/a
n/a
565

40134

403
-69
2

23988
n/a
2454709

425
n/a
435

40250

433
-173
14

13804
n/a
4677351

n/a
n/a
522

40283

420
-478
1

16596
n/a
398107

461
n/a
376

40353

425
-41
14

50199
n/a
162181

n/a
n/a
574

415

3388

448

Donor ID
10374

Table 2: RV217 Early Capture HIV cohort. Longitudinal samples were obtained at pre-infection,
acute, and chronic infection time points for n=7 donors, with the collection date listed as day
relative to first HIV-positive RNA test. Viral load and CD4 counts are listed where available.
Individuals were therapy-naïve at the time of sampling.
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and VV vaccinations (Chapter 2), we also observed increased T-bet MFI in plasmablasts at this
acute time point (Figure 8C). These six individuals remained viremic into early chronic infection
and concomitantly maintained elevated T-bet levels, suggesting a relationship between continued
viral replication and maintenance of this expanded population (Figures 8B and 8C).

+

3.3.2 Chronic HIV infection maintains an expanded T-bet B cell population

+

Having observed the rapid expansion and sustained expression of T-bet B cells in acute to early
chronic HIV infection, we next examined T-bet expression in memory B cells from chronically
+

infected HIV cohorts with different viral loads: viremic HIV progressors (progressors; VL>10,000
copies/ml), viremic controllers (VC; VL 41-1800 copies/ml), elite controllers (EC; VL <40
copies/ml), aviremic individuals on antiretroviral therapy (ART; VL<40 copies/ml), and HIV+

negative controls (Tables 3 and 4). We identified a significant expansion of T-bet memory B cells
in HIV-infected progressors and viremic controllers compared to healthy controls (Figure 9A and
9B). In progressors, individuals with the highest viremia, this expansion was comprised almost
entirely of T-bet

high

CD85j

high

B cells (Figure 9C) and coincided with higher expression levels (MFI)

of T-bet (Figure 9D). Absence of detectable viremia in EC and ART was associated with
+

decreased T-bet B cell population size in many donors compared to viremic individuals (Figure
9B), which could be explained in part by diminished T-bet

high

CD85j

high

cell expansion in these

cohorts (Figure 9E). We also observed a trend toward elevated T-bet expression frequencies in
+

RM B cells in all HIV cohorts (Figure 9F); however, similar to our findings in HIV-negative donors
(Chapter 2, Figure 3C), RM cell T-bet expression levels (MFI) remained low (data not shown).
Lastly, we observed increased T-bet MFI in plasmablasts of progressors and viremic controllers
(Figure 9G), suggesting together with our acute infection findings that viral replication also
promotes T-bet expression in plasmablasts. Together, our data indicate chronic HIV viremia
drives T-bet expression in both memory B cells and plasmablasts and maintains the expansion of
the T-bet

high

CD85j

high

subset.
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Donor ID
110029
110564
110595
110600
110657
110869
110870
110887
111031
111096
110015
110029
110043
110054
110163
110206
110285
110313
110334
110348
110351
110399
110670
110939
110967
111005
111031
111081
111089
111112
111154
110187
110245
110360
110554
110622
110673
110763
110979
111056
111083
111117
130236
130636

Group
ART
ART
ART
ART
ART
ART
ART
ART
ART
ART
ART
ART
ART
ART
ART
ART
ART
ART
ART
ART
ART
Prog.
Prog.
Prog.
Prog.
Prog.
Prog.
Prog.
Prog.
Prog.
Prog.
Prog.
Prog.
Prog.
Prog.
Prog.
Prog.
Prog.
Prog.
Prog.
Prog.
Prog.
Prog.
Prog.

VL
Undetectable
Undetectable
Undetectable
Undetectable
Undetectable
Undetectable
Undetectable
Undetectable
Undetectable
Undetectable
Undetectable
Undetectable
Undetectable
Undetectable
Undetectable
Undetectable
Undetectable
Undetectable
Undetectable
Undetectable
Undetectable
141958
198018
97259
224078
41679
500000
280428
339292
466000
205176
14573
10210
25320
41600
57465
28000
25876
*Undetectable
145654
17284
33940
28888
35160

CD4 ct.
800
1091
702
828
1188
679
693
689
338
686
698
624
564
644
640
423
481
804
431
1438
382
70
248
250
8
221
90
222
377
5
8
393
216
349
777
471
387
270
1323
494
323
364
632
323

54	
  
	
  

130716

Prog.

99562

19

Table 3: University of Pennsylvania Center for AIDS Research donor samples. Viral loads
and CD4 counts for chronically infected HIV+ cohorts, including antiretroviral therapy (ART)treated and ART-naïve, viremic individuals (Progressors), are depicted. The individual marked
with * had undetectable viremia at the time of collection but had a viral load of 18,083 at the
subsequent clinic visit 20 months later.
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Donor ID
1161
1176
1203
1204
1215
1247
1277
1367
1446
1448
1508
1526
1527
1541
1545
1555
1581
1637
3604
4014

Grou
p
VC
EC
EC
EC
VC
VC
VC
EC
VC
VC
VC
EC
EC
VC
VC
EC
EC
VC
EC
EC

VL
360
<40
<40
<40
1183
1102
76.3
<40
305
1400
201
<40
<40
1589
182
<40
<40
676
<40
<40

CD4
ct.
1185
757
890
1032
1747
591
1074
566
1086
485
427
531
1085
1174
625
613
1227
909
912
982

Table 4: University of California San Francisco SCOPE cohort. Viral loads and CD4 counts
for viremic controllers (VL 41-1800 copies/ml) and elite controllers (VL <40 copies/ml) are
depicted. All individuals were therapy-naïve at time of sampling.
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As our data implicate T-bet

high

CD85j

high

cells as participants in antiviral responses, and

members of this population have been described as exhausted during chronic HIV infection (151),
we next asked whether chronic HIV infection might selectively induce transcriptional changes in
T-bet

high

CD85j

high

cells and therefore potentially impact their functionality. We compared RNA

transcript levels of our 91-member panel (Chapter 2, Figure 4A) in T-bet

high

CD85j

high

between HIV-negative individuals (n=4) and progressors (n=5) and found that T-bet

cells

high

CD85j

high

cells appear largely similar regardless of HIV infection status (Figure 9H). These findings suggest
that, while viremic HIV infection greatly expands and maintains the T-bet

high

CD85j

high

population,

it does not overtly alter the transcriptional environment of these cells during the course of
infection.
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Figure 9: T-bet expression in B cells and RNA transcript levels in T-bet

high

CD85j

high

cells

during HIV infection.
(A) T-bet expression in memory B cells of a representative HIV-negative donor and an HIV

+

chronic progressor (progressor). (B) T-bet expression frequency of memory B cells in HIV+

+

negative, progressor, HIV viremic controller (VC), HIV elite controller (EC), and HIV

+
+

antiretroviral therapy-treated donors (ART); n=10 donors per group. (C) Phenotype of T-bet B
cell population from each cohort in B. Bars represent standard error. (D) T-bet MFI of total T-bet
cells from each cohort. (E) Correlation of total T-bet expression and T-bet

high

CD85j

high

+

cell

+

frequencies of memory B cells. Four HIV cohorts are represented by different colors:
Progressors, Prog, black; Viremic controllers, VC, blue; Elite controllers, EC, red; Aviremic
individuals on antiretroviral therapy, ART, gray. Statistics were calculated using Spearman
correlation. (F) Frequency of RM cells expressing T-bet by cohort. (G) T-bet MFI of plasmablasts
by cohort. (H) Comparison of transcript expression levels for 91 gene targets between healthy
donors (n=4) and progressors (n=5). Each dot represents the mean expression value calculated
for HIV-negative donors (x value) and progressors (y value). Lines represent 90% prediction
bands of calculated linear regression. Statistical comparisons in B, D, F, and G calculated using
one-way ANOVA with Tukey’s multiple comparisons test. * denotes a P value 0.05 > P ≥ 0.01. **
denotes a P value 0.01 > P ≥ 0.001. *** denotes a P value < 0.001.
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3.3.3 Sustained T-bet expression in B cells alters the antibody isotype repertoire

As T-bet is associated with specific IgG isotypes (Chapter 2, Figure 2E), we hypothesized that the
maintenance of elevated T-bet expression in B cells and plasmablasts during HIV infection might
alter memory B cell surface IgG isotype distribution and serum antibody repertoires in these
individuals. We therefore analyzed memory B cells from HIV-negative individuals and progressors
and found increased frequencies of IgG1- and IgG3-expressing memory B cells during HIV
infection (Figure 10A). To explore possible downstream effects on secreted antibody, we next
assessed the isotypes of total serum antibody from progressors and age/ethnicity matched HIVnegative controls and found approximately 2-fold increases in titers of IgG1 and IgG3 in
progressors as compared to controls (Figure 10B). IgG1 titers in viremic subjects positively
+

correlated with the frequency of T-bet memory B cells (though this did not reach statistical
significance due to a single outlier), while IgG2, IgG3, IgG4, and IgA titers displayed no
relationship (Figure 10C). IgM titers also positively correlated with T-bet expression frequency
(Figure 10C), suggesting that activation events in early memory B cell differentiation may be
skewed by T-bet expression. In summary, HIV drives the expansion and maintenance of T-bet

+

memory B cells and plasmablasts, which correlate with an overrepresentation of surfaceexpressed and soluble IgG1 and IgG3 during viremic infection.
We next set out to examine the relationship between T-bet activation-induced cytidine
deaminase (AID, or AICDA as transcript), the B cell-specific enzyme that is required for antibody
isotype switching (37). Within the peripheral B cell compartment, AICDA expression is highest in
T-bet

high

CD85j

high

B cells, and transcript levels remain elevated in this subset during chronic HIV

infection (Tables 3 and 5; Figure 10D). To examine the potential regulation of AICDA transcript
expression by T-bet, we performed siRNA-mediated downregulation of T-bet in primary CD21

-

-

CD27 B cells from progressors with high T-bet expression frequencies in this subset (mean
+

93.6% T-bet , range 81.2% to 97.6%; Figure 10E), as previously described (178); cells
consistently retained their CD85j

high

-

phenotype following nucleofection (Figure 10F). CD21 CD27
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-

Figure 10: Antibody isotype expression levels, correlations with T-bet, and siRNA T-bet
knockdown in B cells of progressors.
(A) Frequency of IgG isotype-expressing B cells within total memory B cell compartment of HIV+

negative individuals and progressors (HIV ) (n=10 donors per group). Statistics in A and B
calculated using unpaired t-test. (B) Absolute concentration of total serum antibodies by isotype
+

from progressor (HIV ) and age/ethnicity-matched HIV-negative cohorts (n=10 donors per group).
(C) Correlations between T-bet expression frequency in memory B cells and serum antibody titers
by isotype (ng/ml). Statistics in C calculated using Spearman correlation. (D) AICDA transcript
expression (log2 units) of HIV-negative donors (grey; n=4) and progressors (black; n=5) per B cell
subset. Trans., transitional; RM, resting memory; PB, plasmablast. Each dot represents transcript
expression from one individual. Statistical comparison calculated using repeated measures
-

ANOVA with Tukey’s multiple comparisons. (E) Expression of CD21 and T-bet within CD27 B
-

-

cells from a representative progressor used for CD21 CD27 B cell sorting. (F) CD85j expression
-

-

by sorted CD21 CD27 B cells at 24 and 72 hours post-nucleofection with either control or T-bet
-

-

siRNA, compared to non-nucleofected sample. (G) RT-PCR of AICDA transcript in CD21 CD27 B
cells of progressors transfected with control or T-bet siRNA. Values represent AICDA transcript
level as a fraction of no siRNA treatment condition. Statistical comparison in G calculated using
paired t-test. * denotes a P value 0.05 > P ≥ 0.01; ** denotes a P value 0.01 > P ≥ 0.001.
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Donor ID
OM10
OM17
OM255
OM284
OM5007
OM5031
OM5037
OM5062
OM5220
OM5271
P09586
P09588
P09603
P09636

Cohort
Toronto
Toronto
Toronto
Toronto
Toronto
Toronto
Toronto
Toronto
Toronto
Toronto
UPenn CFAR
UPenn CFAR
UPenn CFAR
UPenn CFAR

Duration
>1 year
<6 months
<6 months
<3 months
<3 months
<1 year
<3 months
>6 months
<3 months
<3 months
2.5 months
>1 year
67 days
6 months

Status
Chronic
Early
Early
Acute
Acute
Chronic
Acute
Chronic
Acute
Acute
Acute
Chronic
Acute
Early

VL
22415
440000
18322
170693
24019
13537
13948
187361
10640
25947
23990
80000
442034
43374

CD4 ct.
132
660
370
430
440
330
780
410
470
320
446
<500
922
605

Table 5: Acute and chronic HIV samples from University of Toronto and University of
Pennsylvania CFAR cohorts. Viral loads and CD4 count for University of Toronto and University
of Pennsylvania cohorts are depicted. The listed duration of infection is estimated: Acute samples
are estimated to have been collected <3 months since infection; Early samples are between 3-6
months since infection; Chronic samples are from greater than 6 months since infection. All
individuals were therapy-naïve at time of sampling.
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B cells were chosen as a representation of the T-bet

high

CD85j

high

population because they can be

identified and sorted via negative selection, avoiding potential ligation effects of CD85j-specific
antibodies. T-bet siRNA knockdown reduced levels of AICDA by 44% compared to control siRNA,
indicating that T-bet at least partially regulates expression of AICDA in this population and may
promote class switching via this regulation (Figure 10G).

+

3.3.4 HIV infection primarily drives a T-bet B cell response to HIV envelope protein gp140

+

Finally, we examined the relationship between T-bet B cells and the B cell response to HIV,
focusing on the Env-specific response since this antigen is the relevant antibody target during
HIV infection (54). Using a group M consensus sequence-derived gp140 protein to capture
soluble antibody in an ELISA format, we analyzed the isotype repertoire of the gp140-specific
antibody in serum of progressors (Table 3) and found that, in agreement with previous studies
(179-184), Env-specific responses are dominated by IgG1 isotype antibodies (Figure 11A), the
most frequent IgG isotype associated with T-bet-expressing B cells. To directly connect this
expanded Env-specific IgG1 usage to the cellular component of the response, we used gp140
protein fluorophore probes to identify gp140-specific B cells via flow cytometry, as previously
described ((152); Figure 11B). Progressors, several of which were estimated to be in the early
+

acute phase of infection, at <3 months HIV (see Table 5), demonstrated a mean gp140-specific
B cell frequency of 0.86% of class-switched B cells in peripheral blood, and this frequency was
+

diminished in HIV cohorts with lower viremia (Figure 11C). Interestingly, nearly all gp140-specific
+

B cells expressed T-bet, regardless of the HIV donor’s viral load (Tables 4 and 5; Figures 11D
and 11E). gp140-specific B cells from HIV viremic individuals consistently demonstrated a Tbet

high

CD85j

high

phenotype, while the gp140-specific B cell response in subjects with lower or

controlled viremia was composed of both T-bet

high

CD85j

high

cells and T-bet

low

RM B cells (Figure

11F and data not shown). Taken together, these findings demonstrate that the humoral immune
+

response to HIV Env is specifically coordinated by the T-bet memory B cell population and
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suggests induction of this transcription factor as a mechanism driving the predominantly IgG1based Ig response to the virus.
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Figure 11: gp140-specific memory B cell phenotypes and serum Ig isotypes.
(A) gp140-specific serum Ig titers by isotype from progressors (n=10). Titers were normalized
using age/ethnicity matched controls. Statistical comparison calculated using repeated measures
one-way ANOVA with Tukey’s multiple comparisons test. (B) Representative staining of gp140-

-

specific class switched (IgD IgM ) memory B cells from a progressor. (C) Frequency of gp140specific cells within total class-switched memory B cells by cohort. n=10 for all cohorts except
progressors (n=11). (D) T-bet expression of gp140-specific B cells (red) and total B cells (black)
from a representative progressor. (E) Frequency of T-bet expression within gp140-specific cells
+

from HIV cohorts (n=10 progressors, n=10 VC, n=6 EC). All donors with <40 gp140-specific cells
(including all ART individuals) were excluded from analyses in E and F. No statistical differences
were observed between donor groups. (F) Frequency of gp140-specific cells with Tbet

high

CD85j

high

phenotype by cohort. For C, E, and F, statistical comparisons were calculated

using one-way ANOVA with Tukey’s multiple comparisons test. * denotes a P value 0.05 > P ≥
0.01; ** denotes a P value 0.01 > P ≥ 0.001. *** denotes a P value < 0.001.
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3.4 Discussion

The identity of the cells and regulatory mechanisms orchestrating the humoral HIV response has
+

remained unclear. We tested the hypothesis that T-bet B cells, which expand during acute
resolving viral infections and express antiviral antibody isotypes, contribute to the HIV response.
+

Similar to YFV and VV vaccinations, acute HIV infection elicits an expansion of T-bet B cells;
however, unlike the transient nature of acute YFV and VV responses, chronic HIV viremia
+

maintains elevated T-bet B cell frequencies that are associated with increased serum IgG1 and
+

IgG3 titers. These T-bet cells dominate the HIV Env-specific B cell response and likely skew the
anti-Env serum antibody repertoire to the IgG1 isotype.
-

In agreement with our previous study of HIV donors (Chapter 2), our current
+

+

+

observations of increased IgG1 and IgG3 memory B cell frequencies in viremic HIV donors
maintaining elevated T-bet expression further support T-bet as a mechanism promoting IgG1 and
IgG3 isotype switching. Memory B cells do not actively secrete antibody; however, viremic HIV

+

individuals also displayed increased T-bet MFI in plasmablasts, increased total IgG1 and IgG3
serum titers, and an IgG1-dominated Env-specific serum antibody response, suggesting IgG1
+

+

and IgG3 antibody-secreting cells readily differentiate from or share a similar origin with IgG1

+

+

and IgG3 memory B cells. It is unclear why IgG3 antibodies are not more prevalent within the
anti-Env antibody repertoire during chronic HIV infection when T-bet expression is high, but IgG3
levels have been demonstrated to peak early during HIV infection and wane over time (54). It is
possible that sustained HIV viremia drives recurrent germinal center re-entry and isotype
switching of memory B cells, which could promote splicing out of the proximally located γ3 gene
from the constant region locus as the infection progresses; indeed, a recent study suggests class+

+

+

switching of IgG3 B cells would likely give rise to either IgG1 or IgG2 cells (185). Together, our
findings suggest T-bet expression in B cells coordinates the IgG1-dominated anti-Env response
and likely regulates antibody isotype selection during other human viral infections.
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AID expression is tightly controlled by multiple factors (38), but our siRNA T-bet
knockdown experiments suggest that T-bet may regulate IgG1 and IgG3 class switching in part
by promoting AICDA expression, although it is unclear whether this occurs by direct or indirect
mechanisms. In addition to isotype switching, AID is required for somatic hypermutation (37), the
diversification of antibody binding sites. Therefore, by regulating AICDA, T-bet may also promote
antibody mutation, and a recent murine study supports this notion by demonstrating significant
mutation rates in BCRs from T-bet-expressing B cells (186). However, antibody mutation may be
+

impaired in subsets of T-bet B cells during progressive HIV infection, as HIV-specific antibodies
derived from TLM cells demonstrated diminished mutation levels compared to RM cell-derived
antibodies (187). Future studies should examine whether relatively low TLM antibody mutation
rates are typical (i.e. observed in healthy individuals mounting successful humoral responses) or
are instead reflective of immunopathology specific to chronic HIV infection; in support of the latter
possibility, malaria-specific antibody derived from TLM-phenotype B cells displayed higher
mutation rates than those derived from RM cell counterparts (188).
+

HIV cohort analyses identified involvement of both T-bet
and T-bet

low

roles. T-bet

+

+

high

-

(CD21 T-bet

high

CD85j

high

)

low

(CD21 CD27 T-bet ) B cell subsets in the HIV response, with potentially divergent

high

cells were induced early and maintained the Env-specific B cell response during

chronic viremic HIV infection, with a reduction in T-bet

high

population size following natural or

therapy-mediated control of viremia. Combined with our YFV and VV observations (Chapter 2),
these findings suggest T-bet

high

cells are a major component of acute and chronic antiviral B cell

responses and, in the setting of HIV, are responsive at a population level to modulation of viremia
and immune activation. Conversely, reduction of viremia during chronic HIV infection did not
affect expanded T-bet

low

RM cell population size, suggesting these cells do not depend on viral

replication for their maintenance. Viral control was also associated with a greater representation
of T-bet

low

cells within the Env-specific pool, suggesting the Env-specific response is mediated by
+

different T-bet B cell subsets depending on disease course: T-bet
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high

cells during acute infection

and settings of high viremia, and T-bet

low

B cells in the context of controlled but persistent low

level viremia.
-

We and others have previously demonstrated an expansion of CD21 B cell subsets
induced by Th1-type human infections, including HIV, Malaria, and Hepatitis C (120, 150, 151,
-

160, 161, 165, 189, 190), and expansion of a clonal CD21 subset has been described during
Hepatitis B- and Hepatitis C-associated mixed cryoglobulinemia (191-193). Interestingly,
-

maintenance of expanded CD21 cells in each of these infections appears to be dependent upon
-

pathogen load (150, 151, 189, 194-196). Our current findings, combined with the similar CD21 B
-

cell phenotypes described in these studies, suggest that CD21 B cell expansion associated with
these various Th1-type infections may in part be explained by infection-induced T-bet expression
and expansion of T-bet

high

CD85j

high

cells. In support of this hypothesis, murine experiments

+

suggest the T-bet B cell phenotype is induced by concerted actions of pathogen-derived nucleic
acids (TLR7 or TLR9 stimulation; (113-117, 197)) and cytokines produced during Th1-type
infections (IFNg and IL-21; (65, 78, 116)) on B cells. Still, additional studies are necessary to
determine the relationship between acute viral infection-induced T-bet

high

CD85j

high

cells and these

-

chronic infection expanded CD21 B cell subsets. Interestingly, observational human studies
-

further demonstrate similar CD21 B cell expansion during various autoimmune diseases (73,
119, 121, 162, 163, 166), and murine models indicate TLR sensing can stimulate T-bet
-

expression to drive expansion of autoantibody-producing B cells (78, 115), suggesting CD21 T+

bet B cells may also play a role in human autoimmune diseases.
+

While our YFV and VV acute infection observations (Chapter 2) suggested T-bet B cells
generally represent a component of the antiviral B cell response, we specifically demonstrated
+

that T-bet B cells compose nearly the entire detectable peripheral B cell HIV Env memory
+

response, beginning at least during early (<3 months HIV ) infection. As such, most gp140+

specific antibodies likely derive from descendants of the T-bet B cell population or share a
similar T-bet-regulated origin in both progressors and individuals controlling viremia. This likely
also includes HIV-specific broadly neutralizing antibodies, but requires further assessment as
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previous studies that isolated broadly neutralizing antibodies from B cells generally did not
+

consider the nature of the cells. An important question remaining is the degree to which T-bet B
cells and derived antibodies contribute to control of viremia during HIV and other viral infections.
+

Indeed, while a murine study demonstrated the requirement of T-bet B cells to control chronic
LCMV viremia to low levels (118), the role of B cells and immunoglobulin in ongoing control of
HIV/SIV remains controversial (198-202). However, it is highly likely that an efficacious HIV
vaccine will need to induce HIV Env-specific broadly neutralizing antibodies. As such, our results
directly demonstrate the importance of T-bet-expressing B cells to the HIV-specific humoral
response.
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CHAPTER 4
	
  
CONCLUSIONS, IMPLICATIONS, AND FUTURE DIRECTIONS
Introduction
A more complete understanding of B cell biology is critical for the development of
vaccines and other interventions to improve humoral immunity to viruses, particularly in the case
of HIV infection. As such, we sought to better define the cellular members and mechanisms that
directly promote human antiviral responses and help to maintain humoral memory. In chapters 2
and 3 of this dissertation, we identified a previously unappreciated T-bet-expressing B cell
population and described a number of characteristics, including cell phenotypes, population
+

dynamics, and tissue localization, that identify human T-bet B cells as a unique viral infectionresponsive subset. Our findings provide critical insights into the T-bet-regulated generation of
+

humoral viral responses, identify T-bet B cells as the specific mediators of the HIV Env
response, and raise a number of questions that provide a framework for further dissecting the
+

biology of human T-bet B cells. The conclusions, implications, and future directions of this
dissertation’s key findings will be discussed below.

T-bet as a mediator of Th1 immunity in human B cells
Recent murine studies demonstrate a role for T-bet-expressing B cells in viral control
(117, 118), but the mechanisms driving antiviral immunity in human B cells are poorly understood.
Our observed induction of T-bet expression across the B cell compartment during diverse acute
viral infections (low versus high viremia and inflammation; RNA versus DNA viruses) and chronic
HIV infection strongly suggests a role for T-bet as a critical regulator of antiviral humoral immunity
-

in humans. T-bet’s association with IgG1 and IgG3 antibody isotypes in both HIV individuals and
those mounting a substantial HIV immune response identifies promotion of class switching as an
important function mediated by the transcription factor to combat viruses. Our findings further
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suggest that T-bet expression promotes the differentiation of a unique activated B cell subset to
mediate the acute antiviral response and maintains a resting memory pool prepared to initiate
secondary immune responses (discussed further below). Via these diverse mechanisms, T-bet
appears to broadly coordinate humoral antiviral immunity in humans.
The substantial induction of T-bet during acute viral responses, particularly in the T-bet

high

subset, suggests T-bet may act as a master regulator of Th1-type B cell development. However,
it is unclear whether T-bet is sufficient to drive Th1 B cell development in humans or is simply a
marker of this program, acting as a minor player within a larger transcriptional network. In support
of the former possibility, T-bet controls a broad transcriptional program in T cells and is required
+

+

for both Th1 CD4 T cell development and the generation of IgG2a B cell responses in mice (78,
+

99). Our findings suggest human B cell development mirrors that of CD4 T helper cell
differentiation (i.e. Th1 vs. Th2) in which cytokines and other signals guide specific differentiation
+

pathways at the expense of others (203). Subsequent analyses of T-bet B cell differentiation,
polarization, and plasticity will be best explored in murine models.
The exclusivity of T-bet in regulating human B cell immune responses to viruses versus
other pathogens is an important question that has not been assessed. The expansion of cells
resembling our T-bet

high

population in other Th1 infections such as malaria suggests T-bet

functions more broadly to promote humoral responses to intracellular pathogens (160).
Additionally, IL-4 inhibits the T-bet transcriptional program in murine B cells, suggesting T-bet is
not involved in Th2 B cell responses (116). Future work should assess T-bet induction and Tbet

high

cell activation in the context of non-viral Th1 infections and also infections predicted to

poorly elicit Th1 immunity, such as encapsulated bacteria or helminthes, to definitively define the
pathogen responses T-bet regulates. Lastly, it should be noted that our findings suggesting an
overwhelmingly T-bet-mediated humoral response to human viral infections do not rule out the
-

involvement of T-bet subsets in aspects of the response.
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T-bet

high

B cells as a novel antiviral population
+

In another central finding of this study, we identified a novel T-bet viral infectionresponsive subset of memory B cells in healthy individuals. A number of observations support the
hypothesis that T-bet

high

B cells are primed for acute viral infection responses: T-bet

high

cells are

enriched for IgG1 and IgG3 isotypes in healthy individuals, express a distinct trafficking receptor
profile potentially facilitating tissue and inflammation-directed migration, demonstrate an activated
phenotype and propensity to expand 2-4 weeks after infection with live replicating viral vaccines
or HIV, expand and contract in concert with viremia during HIV infection, and dominate the HIV
+

Env-specific B cell response in viremic HIV progressors. Many of T-bet
characteristics mirror those of effector T cells (100), suggesting T-bet

high

high

cells’ distinctive

cells are the specific B

cell subset mediating the active humoral response to acute human viral infections (Figure 12).
Our study further suggests that T-bet

high

cells are not a subset of classical memory B cells

or antibody-secreting cells; instead, based upon their distinct transcriptional and phenotypic
profiles and immune response kinetics compared to resting memory (RM) B cells and
plasmablasts, they are likely a separate type of cell within the B cell lineage. This notion is
supported by phylogenetic studies of CD21

low

B cells that identified both distinct CD21

low

clades

and clonal relationships between these cells and the RM cell and plasmablast populations (204).
T-bet

high

cells’ functional niche within the human humoral immune system is still unclear, but our

transcriptional analyses identified intermediate expression of antibody-secreting programpromoting transcription factors (IRF4, PRDM1, and XBP1), suggesting these cells may be primed
to quickly differentiate into antibody-secreting cells and contribute to the antibody response. Their
distinctive trafficking receptor profile further suggests specialized migratory capacity, and murine
studies suggest they may be capable of producing cytokines such as IFNg upon stimulation (65).
Future analyses should focus on elucidating the specific functions mediated by T-bet

high

B cells

during acute viral infections.
We also identified a unique tissue compartmentalization of T-bet

high

cells: unlike

plasmablasts and RM cells, which were identified in lymphoid tissues and can re-circulate back
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Figure 12: Model proposing the induction and differentiation of T-bet-expressing B cells by
viral infections.
T-bet is induced in B cells by TLR/cytokine/BCR stimulation during acute viral infection, leading to
T-bet

high

cell development. Upon viral clearance (yellow fever virus (YFV) and vaccinia virus (VV)

vaccinations), the blood T-bet

high

subset contracts in size, potentially due to trafficking of cells into
low

tissues, differentiation into a resting phenotype (T-bet ), or cell death. However, during chronic
HIV infection, persistent viral replication and immune activation induce expansion and
maintenance of a large T-bet

high

B cell pool that will return to normal size only upon control of

viremia via antiretroviral therapy (ART).
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into the blood, T-bet
curious T-bet

high

high

cells appear to be largely absent from lymphoid tissues (except for a

+

CD21 population in the spleen) and, based upon their absence from thoracic

duct fluid, may not return back into the blood after they exit. Together, these observations
suggest T-bet

high

cells do not re-circulate in the absence of a significant immune response and

raise questions regarding their trafficking and tissue localization. CD11c and CXCR3 expression
would be predicted to enable tissue trafficking toward sites of inflammation, so T-bet

high

cells may

migrate from the blood directly into tissues where infection occurs. However, our data suggests Tbet

high

cells do not return to the blood and instead may either reside permanently in these tissues

or undergo apoptosis after completion of the acute immune response (Figure 12). Regardless, Tbet

high

cells’ tissue distribution and circulatory patterns indicate that lymphoid tissue immune

surveillance (analogous to that of naïve and RM cells) is not a primary function of this subset.
Our findings are complemented and informed by two recent studies of early acute
antigen-specific responses to infection and vaccination (159, 204). The first by Ellebedy et al.
identified an activated, CD21

low

B cell subset expressing CD71 that emerged acutely following

influenza infection, ebola infection, and influenza vaccination, and contained the majority of
influenza-specific B cells (159). While the second by Lau et al. did not detect a clear population
expansion, the authors found a concentration of influenza-specific cells in the CD21
acutely following vaccination and an enrichment of T-bet expression in CD21
phenotype hemagglutinin-specific cells (204). In both cases, the cells’ CD21

low

low

low

- and RM-

phenotype and

population dynamics during the acute immune responses suggest they are likely T-bet
Together, these studies extend our findings of T-bet

high

high

high

B cells.

cells in influenza and Ebola

cells can also be activated during secondary responses

(influenza) and by non-replicating viruses (inactivated influenza vaccine).
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high

cell activation in primary YFV, VV, and

HIV infections by implicating a broader involvement of T-bet
responses and suggesting T-bet

population

T-bet

low

B cells as a quiescent memory population
In addition to Tbet

high

cells, our study identified a counterpart T-bet

RM B cell population. As their name suggests, T-bet

low

low

subset within the

cells express T-bet at a low MFI that is

difficult to confidently detect using most intracellular cytokine staining protocols. This population
differs significantly from Tbet

high

cells in a number of other phenotypes and behaviors, including

consistent CD21 and CD27 expression, minimal signs of activation, an unresponsiveness to
acute viral infections in terms of activation and expansion (at the population level), and a
widespread lymphoid tissue distribution with the ability to re-circulate back into the blood. These
characteristics are largely consistent with a resting, long-lived memory B cell phenotype (151); as
such, we speculate that T-bet

low

cells represent a reservoir of virus-specific clones that function to

maintain long-lived humoral memory to viral infections and facilitate rapid responses upon antigen
re-encounter. The existence of a human T-bet

low

memory population is supported by mouse

+

models in which IgG2a memory B cells require consistent low-level T-bet expression to maintain
their integrity well after class-switching has completed (112).
If T-bet

low

cells are indeed a resting, virus-specific reservoir, T-bet

high

cell clones

generated early during acute viral infection would be predicted to seed the T-bet

low

population

upon resolution in the contraction phase (Figure 12). In support of this phenomenon, influenzaspecific, acutely activated CD21

low

clones have been demonstrated to enter the long-lived
-

-

memory pool (159), and common origins of pathogen-specific TLM (CD21 CD27 ; almost certainly
T-bet

high

cells based on our findings) B cells and RM cells have been described during HIV

infections (187). In our own study, the T-bet

low

population increasingly maintained the Env-

specific memory B cell pool upon control of viremia and subsequent contraction of the T-bet
subset, and T-bet

low

cells’ maintenance in the absence of detectable HIV viremia suggests an

ability to survive independent of antigen and significant inflammatory signals.
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high

Plasmablasts can express T-bet
Previously, Wang et al. described low-level T-bet mRNA expression in plasmablasts
during a hapten response in mice (112). To our knowledge, ours was the first study to identify Tbet protein expression in plasmablasts. T-bet was essentially undetectable in the plasmablasts of
healthy individuals in the absence of an immune response; however, YFV- and VV-vaccinated
individuals reproducibly exhibited a significant spike in plasmablast T-bet MFI that peaked around
+

2 weeks post vaccination but remained lower than the MFI in T-bet memory B cells. T-bet MFI in
plasmablasts also increased during acute HIV infection and was maintained at an elevated MFI in
chronically infected individuals, suggesting T-bet induction may contribute to the IgG1-focused
hypergammaglobulinemia characteristic of viremic HIV infection. T-bet’s function in plasmablasts
is unclear, but it may be required for the continuous transcription of IgG1 and IgG3 that would
occur in cells constitutively producing antibody (112). T-bet may also help plasmablasts traffic to
sites of inflammation by promoting CXCR3 expression.

+

Human spleen is a T-bet B cell-rich organ
+

+

Our identification of a massive CD21 T-bet B cell population in human spleen was
particularly surprising since the magnitude more closely resembled reactive lymph nodes than the
non-reactive nodes assessed in our study (123). It remains possible that this phenomenon is the
+

result of unrecognized inflammation in our spleen samples, but the consistently large CD21 T+

bet population in all six donors suggests this is a common phenotype. Our panel was insufficient
+

to determine the identity of these cells and their relationship to peripheral T-bet subsets, but they
+

+

+

+

were chiefly comprised of cells with marginal zone B cell-like (CD21 CD27 IgM IgD ) and class+

+

-

-

switched memory-like (CD21 CD27 IgM IgD ) phenotypes. Interestingly, we also detected T-bet
+

-

+

expression in phenotypically naïve cells (CD21 CD27 IgD ), suggesting the spleen may be a site
+

+

+

of T-bet B cell activation. The considerable population size of splenic CD21 T-bet B cells
suggests a portion of these cells may be spleen-resident, raising the possibility that human
+

spleen acts as a reservoir of T-bet B cells. Histological, transcriptional, and phylogenetic studies
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are necessary to identify the localization of these cells (white pulp, red pulp, or marginal zone)
+

and determine their relationship to peripheral blood T-bet B cells.

Tissue-like memory B cells are not inherently dysfunctional
Our data identify an association between T-bet

high

B cell induction and protective vaccine-

induced antibody responses, and this connection is further supported by influenza studies (159,
+

204) and T-bet B cells’ clear association with control of viral load in mice (117, 118). Together,
these studies suggest T-bet

high

cells are not a functionally impaired developmental aberration and

are instead a normal component of acute humoral responses. This notion has implications for the
HIV-specific B cell response (discussed below), but it also contradicts a prevalent conviction that
tissue like memory (TLM) cells, a large component of the T-bet

high

population, are inherently

dysfunctional (151). Expansion of this normally rare population during chronic infectious diseases
(120, 151, 160) and autoimmune diseases (73, 119, 162, 163) is generally interpreted as
evidence of an aberrant differentiation state, and in some cases such as SLE, these cells do
contribute to pathology (119). However, in the context of HIV infection, our findings suggest that
T-bet

high

(and TLM) cell expansion is a product of uncontrolled viral replication and inflammation

continuously directing newly activated B cells along the T-bet
bet

high

high

differentiation pathway. Since T-

population size returns to normal upon control of viremia, we propose that HIV is simply

driving the consistent development of a normally transient population. Importantly, our findings do
not rule out the possibility that T-bet

high

B cells with a TLM phenotype effectively participate in

acute viral responses but specifically undergo exhaustion and become dysfunctional if they are
abnormally maintained for an extended period of time in the presence of high antigen load (205).
Functional studies comparing T-bet

high

-

+

cells in HIV and HIV individuals are necessary to

definitively rule out this possibility, but our phenotypic and transcriptional comparisons in these
cohorts suggest T-bet

high

cells themselves are largely unchanged by chronic infection.

Several TLM cell characteristics interpreted to reflect dysfunction or anergy can be
explained by the biology of the T-bet

high

B cell subset. First, TLM cells poorly respond to
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traditional BCR-based stimulation in vitro (151). This property has been confirmed in murine
+

models, which suggest T-bet B cells are a subset with distinct requirements for activation.
+

BCR/CD40 stimulation poorly activates mouse T-bet B cells, while BCR and concomitant TLR7
and TLR9 stimulation potently drive activation of this subset (114, 115). Analyses of human TLM
+

B cells have largely failed to assess these combinations known to efficiently activate T-bet B
cells and may therefore misrepresent the cells’ capacity for responsiveness. In combination with
+

IFNg and IL-21, TLR7 and TLR9 stimulation also efficiently drive T-bet B cell differentiation from
precursors (116), suggesting HIV infection likely induces T-bet in human B cells by directly
providing TLR7 and TLR9 ligands (206-210) and indirectly stimulating production of Th1associated cytokines (IL-12, IL-15, IL-18, TNF, and IFNg) during both acute and chronic phases
of infection (211-213).
Second, TLM cell-derived HIV Env-specific antibodies have been described as inferior,
demonstrating decreased somatic hypermutation and HIV neutralization capacity compared to
-

+

resting memory B cells (187). In line with this observation, analyses of human CD27 IgG B cells
(a large component of the TLM population) and CD21

low

cells strongly suggest T-bet

high

(and

TLM) cells are relatively recent germinal center emigrants and, as such, would be expected on a
population level to demonstrate reduced affinity maturation compared to the mature resting
memory pool (72, 73, 204). It remains possible that TLM-phenotype cells exhibit HIV infectionspecific antibody maturation deficits due to impaired B cell help, but antibodies derived from
Plasmodium falciparum-specific TLM B cells are highly mutated and neutralize comparably to
antigen-specific resting memory B cell counterpart (188), suggesting diminished antibody
mutation is not necessarily characteristic of TLM-phenotype cells.
Lastly, with regard to the aforementioned points, it becomes difficult to extrapolate from
TLM B cell findings and relate these to T-bet
-

high

cells as most TLM B cell studies are complicated

-

by CD21 CD27 population heterogeneity: we and others identified significant differences between
+

-

the T-bet and T-bet subsets that together comprise the TLM B cell population (171), but studies
have generally assessed the TLM population as a whole. Accordingly, future analyses should
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+

specifically focus on the characteristics of the T-bet TLM B cell population to understand the role
of TLM B cells during infection.

+

T-bet B cells dominate the memory B cell response to HIV Env
+

Our surprising identification of T-bet B cells as mediators of the HIV Env response is a
critical finding that generates a number of questions and holds implications for HIV immunity and
+

vaccine efforts. This observation definitively confirms T-bet B cells as mediators of humoral
antiviral responses, a concept that was implicated by our YFV and VV response data, and further
suggests T-bet induction as the mechanism promoting an IgG1-focused Env-specific antibody
response in HIV-infected individuals. An important question remaining is the degree to which
+

expanded T-bet B cells in infected individuals are virus-specific, as our HIV gp140 probe cannot
capture all Env-specific cells and B cell responses generated against other HIV proteins such as
Gag were not assessed. HIV infection is characterized by polyclonal B cell activation (147), and
the excessive magnitude of T-bet induction suggests bystander activation may contribute to the
+

expanded T-bet B cell population, but our findings indicate that the T-bet-regulated response is
at least partially virus-specific.
As T-bet induction in B cells is critical for control of murine viral infections and associates
with protective vaccine responses in humans, we originally hypothesized that an inability to mount
+

a T-bet B cell response might partially explain the shortcomings of humoral immunity during HIV
infection. However, our identification of a Th1-biased, T-bet-regulated B cell and antibody
response in both viremic and controlling individuals suggests the humoral immune system
mounts an appropriately focused B cell response to HIV Env, even in settings of
immunopathology. While B cell development does not seem to be misdirected by HIV per se, a
number of other HIV infection-related factors may impede the T-bet-regulated response and
+

prevent timely development of broad neutralization, including loss of CD4 T cell help, disruption
of lymphoid tissue architecture, and the difficult antigenic nature of the virus.
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+

Humoral immunity (and T-bet B cells by extension) cannot effectively neutralize and
clear HIV in infected individuals. However, as antibodies can put significant pressure on the virus
+

(138, 140, 214), an important question remaining is whether T-bet B cells can still contribute to
+

the HIV immune response. T-bet B cells and their antibodies are critical for maintaining low level
chronic viremia in mouse models (117, 118), and several human and macaque B cell depletion
studies demonstrate a loss of HIV/SIV set point control upon B cell and neutralizing antibody titer
+

decline (198, 200, 202), together suggesting that the T-bet B cell-mediated antibody response
may contribute to the maintenance of set point viremia in some cases. A tractable model would
be necessary to decisively determine this, but human studies assessing the relationship between
T-bet induction and immunological or disease outcomes may provide insight into T-bet’s potential
role in the immune response (e.g. does an earlier B cell T-bet response or one of greater
magnitude correlate with viral set point or development of neutralization breadth?). In any case,
our findings suggest that any humoral immunity-based pressure on the virus is likely derived from
+

T-bet B cells and the HIV Env antibody response they regulate.

Considerations for vaccines
+

Perhaps most importantly, our findings identify both T-bet itself and T-bet B cells
(particularly the T-bet

high

subset) as targets of interest for vaccines and therapeutic interventions

attempting to induce or manipulate Th1-focused humoral immunity. Similarly, T-bet induction in B
cells could serve as a reliable biomarker to assess vaccine candidates’ ability to drive Th1 B cell
programs. Recent immune correlates analyses of the RV144 HIV vaccine trial identified an
association between the elicitation of IgG3-isotype antibodies and reduced infection risk (215,
216), suggesting T-bet induction may be directly relevant to future vaccine efforts attempting to
consistently recreate this response. TLR7/8 and TLR9 adjuvants may hold promise for promoting
T-bet-regulated vaccine responses, and a number of studies show that these adjuvants
significantly improve the quality of antibodies generated by vaccination (217, 218). In summary, a
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+

more detailed understanding of T-bet B cell biology will be informative for the development of
interventions to improve humoral immunity to viruses.
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CHAPTER 5
MATERIALS AND METHODS

Study participants:
Acute infection studies: Five healthy, HIV-negative individuals received live-attenuated
YFV-17D vaccine (YF-Vax, Sanofi Pasteur) and seven different healthy, HIV-negative individuals
received live vaccinia smallpox vaccine (Dryvax, Wyeth Laboratories). Peripheral blood
mononuclear cell (PBMC) samples were obtained on or near day of vaccination and at several
+

subsequent time points (see Table 1 for donor information). Seven acutely infected HIV donors
were enrolled in the RV217 Early Capture HIV Cohort run by the US Military HIV Research
Program. PBMC sample timing was calculated relative to first positive HIV RNA test (Abbot RealTime HIV-1 assay, Abbot Laboratories, Abbott Park, IL). Samples included a pre-infection time
point (ranging 478-41 days previous to first positive HIV RNA test.), an early acute infection time
point (ranging 1-21 days after first positive test; these were collected during or shortly after peak
acute viremia and are considered to represent an early acute infection time point), and a chronic
infection time point (see Table 2). Individuals were antiretroviral therapy-naïve at all sample time
points assessed.

Tissue studies: Paired blood and thoracic duct fluid samples were obtained from individuals with
idiopathic or trauma-based chylopericardium or chylothorax requiring intervention at the Hospital
of the University of Pennsylvania. Lymphoid tissue samples (mesenteric lymph node, iliac lymph
node, tonsil, and spleen) were obtained at the Hospital of the University of Pennsylvania and
Case Western Reserve University: mesenteric and iliac lymph nodes were obtained as normal
structures during abdominal surgery and kidney transplant surgery, respectively. Non-enlarged
tonsils were obtained from sleep apnea patients. Spleens were removed and obtained due to
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trauma or surgical intervention. Mononuclear cells were mechanically separated from solid
tissues and enriched using a ficoll gradient.

+

Chronic HIV infection studies: PBMCs and serum from ART-naïve, viremic HIV individuals
+

(referred to as progressors) and PBMC from ART-treated, aviremic HIV individuals (referred to
as ART) were obtained from the University of Pennsylvania Center for AIDS Research (CFAR;
see Supplementary Tables 1 and 3). HIV-negative serum samples age- and ethnicity-matched to
+

the ART-naïve, viremic HIV individuals were obtained from Case Western Reserve University.
PBMCs from viremic controllers and elite controllers (VC and EC, respectively) were obtained
from individuals enrolled in the SCOPE study at the University of California San Francisco (see
Supplemental Table 2). Additional progressor PBMCs were obtained from the University of
Toronto (see Supplemental Table 3). Healthy HIV-negative human donor PBMC samples were
obtained from the University of Pennsylvania Human Immunology Core.

Antibody reagents:
The following antibodies were obtained from Biolegend: CD19 BV785 (clone HIB19),
CD3 APC-Cy7 and BV570 (clone UCHT1), IgM BV605 (clone MHM-88), CD21 PECy7 (clone
Bu32), CD27 BV650 (clone O323), CD38 BV421 and BV711 (clone HIT2), CXCR3 BV711 and
APC (clone G025H7), CD86 BV605 (clone IT2.2), CD10 BV605 (clone HI10a), CD71 FITC (clone
CY1G4), PD-1 BV421 (clone EH12.2H7), CD8 BV711 (clone RPA-T8), CD56 BV605 (clone
5.1H11), CD16 PECy5 (clone 3G8). The following antibodies were obtained from BD
Biosciences: CD14 APC-Cy7 (clone MØP9), CD16 APC-Cy7 (clone 3G8), IgD PECF594 and
AF700 (clone IA6-2), IgG AF700 (clone G18-145), CD85j FITC (clone GHI/75), Ki67 AF700 and
FITC (clone B56), CD21 BV421 (B-ly4), CD95 PECy5 (clone DX2), Bcl-6 PE (clone K112-91).
The following antibodies were obtained from eBiosciences: T-bet PE and PECy7 (clone
eBio4B10), CD10 PECy5 (clone eBioCB-CALLA), CD11c PECy5.5 (clone 3.9), CD85j APC (clone
HP-F1), CD7 PECy7 (clone 124-1D1), Eomesodermin AF647 (clone WD1928). CD69 PECy5
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(clone TP1.55.3) was obtained from Beckman Coulter. The following antibodies were obtained
from Southern Biotech: IgG1 PE (clone HP6001), IgG2 AF488 (clone HP6002), IgG3 AF647
(clone HP6050). IgA FITC (polyclonal) and CD4 PECy5.5 (clone S3.5) were obtained from
Invitrogen. FcRL4/5 antibody (clone 2A6) was gifted by Max D. Cooper (Emory University,
Atlanta); this antibody was initially characterized as FcRL4-specific, but a recent study
demonstrated clone 2A6 reacts with both FcRL4 and FcRL5 (56).

Antibody staining, flow cytometry acquisition, and analysis:
Cryopreserved PBMCs (or mononuclear cells from other tissues) were thawed, counted,
examined for viability, and rested overnight at 37°C and 5% CO2 in RPMI with 10% fetal bovine
serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin added. All incubations
during the following staining process were performed at room temperature in the dark. On the
following morning, PBMCs were washed with PBS and stained for viability with aqua aminereactive viability dye (Invitrogen) for 10 minutes. Cells were stained with a prepared cocktail of
surface antibodies for 25 minutes, washed once with PBS plus 0.1% sodium azide and 1% BSA,
and fixed/permabilized using the eBiosciences FoxP3 Transcription Factor buffer kit (cat# 005523-00). Intracellular targets were stained with a separately prepared cocktail of antibodies for
60 minutes, washed with the eBioscience kit buffer, fixed with PBS plus 1% paraformaldehyde,
and stored in the dark at 4°C until acquisition. RV217 cohort samples (Figures 2G, 2H) were
stained identically except BD Cytofix/Cytoperm Kit (Cat. # 554722) was used to fix/permeabilize
cells for intracellular staining. Compensation controls were produced with antibody capture beads
(BD Biosciences) for each antibody and ArC Amine Reactive beads (ThermoFischer Scientific)
for aqua amine-reactive dye. All flow cytometry data was collected on a modified LSR II (BD
Immunocytometry Systems). Data was analyzed using FlowJo software (TreeStar). Graphs were
created and statistical analysis was performed using GraphPad Prism (version 7.0a).
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HIV gp140 probe staining:
Recombinant group M consensus gp140 protein was produced and conjugated to Brilliant
Violet 421 and Alexa Fluor 647 fluorophores, as previously described (152, 219). Washed
PBMCs were pre-treated with anti-CD4 (clone SK3, Biolegend) previous to aqua amine-reactive
dye staining to prevent interactions between gp140 probe and CD4. gp140 probe was then added
to surface marker cocktail and staining procedure was completed as described above.

Serum antibody characterization:
HIV-1 specific and total IgG1- IgG4, IgA and IgM were measured on a Bio-Plex
instrument (Bio-Rad) as previously described (136, 215, 220). gp140-specific antibodies were
captured using the same group M consensus sequence protein from gp140-specific cell staining
(see above).

Cell sorting and Fluidigm Biomark transcript analysis:
PBMCs from HIV-infected and –uninfected patients were thawed and rested overnight.
After being washed in PBS, the cells were incubated with amine-reactive viability dye for 10
minutes and stained with an undiluted cocktail of surface antibodies at room temperature. Cells
were washed and resuspended in R10. One hundred cells each from different B cell populations
were sorted on a FACS Aria II (BD Biosciences) into individual wells of a 96-well PCR plate
according to the gating strategy depicted in supplemental figure 1A. Each well contained 5 µL
lysing buffer, consisting of 4.725 µL of DNA Suspension Buffer (10 mM Tris, pH 8.0, 0.1 mM
EDTA; TEKnova), 0.025 µL of 20 U/µL SUPERase•In™ (Ambion) and 0.25 µL of 10% NP40
(Thermo Scientific). After FACS sorting, PCR plates were frozen and kept in -80°C until usage.
PCR plates were thawed on ice and pre-heated for 90 seconds at 65°C. Subsequently, 1 µL
Reverse Transcription Master Mix (Fluidigm) was added to each well and placed into a
thermocycler for reverse transcription (25°C for 5 min, 42°C for 30 min, 85°C for 5 min). Next, 4
µL of a pre-amplification mix, consisting of 1 µL pooled mixture of all primer assays (500nM), 2 µL
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5× PreAmp Master Mix (Fluidigm) and 1 µL H2O, was added to each well and run on a
thermocycler (95°C for 5 min followed by 18 cycles: 96°C for 5 sec 60°C for 6 min). To remove
excess primers, 4 µL of an Exonuclease mixture, containing 0.8 µL 20 units/µL of Exonuclease I
(New England BioLabs), 0.4 µL 10× Exonuclease I Reaction Buffer (New England BioLabs), and
2.8 µL H2O was added to each well. The plate was run on a thermocycler (37°C for 30 min, 80°C
for 15 min). Each well was then diluted (1:4) with DNA Suspension Buffer (10 mM Tris, pH 8.0,
0.1 mM EDTA; TEKnova). In a new PCR plate, distinct primer assays were generated by adding
individual primer pairs (5µM) together with a mix of 2.6 µL 2x Assay Loading Reagent (Fluidigm)
and 2.4 µL 1x DNA suspension buffer to each well. Similarly, a sample PCR plate was created by
dispensing 4 µL of a sample master mix containing 3.5 µL 2x Sso Fast EvaGreen Supermix with
Low ROX (Bio-Rad), 0.35 µL 20x DNA Binding Dye Sample Loading Reagent (Fluidigm) and 0.15
µL H2O to each well. An additional 3 µL of pre-amplified samples were added to each well.
Control line fluid (Fluidigm) was injected to the 96.96 Dynamic Array chip (Fluidigm) and the chip
was primed using an IFX Controller HX. After priming the chip, 4.5 µL of the primer assays and 5
µL of the sample mix were added to detector inlets of the chip and transferred to the IFX
Controller HX for loading the mixtures. The chip was then transferred to a Biomark HD instrument
(Fluidigm) and run using the GE Fast 96x96 PCR+Melt v2.pcl program. All primers were
purchased from IDT and assay efficiency as well as melting and amplification curves for each
assay were evaluated beforehand on a separate Biomark HD run with similar sorted B cell
populations. All data were pre-analyzed with the Real-time PCR analysis software (Fluidigm), and
Linear (Derivative) and User (Detectors) were used as settings to generate Ct values. A
conservative Ct value of 25 was used as limit of detection (LOD). Relative gene expression was
defined as a log2 value based on: log2 = LOD–Ct. All subsequent analysis of the gene expression
data, including tSNE analysis and hierarchical clustering, were performed using R Studio.
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T-bet siRNA knockdown:
-

-

+

Mature CD21 CD27 B cells from viremic HIV donors were transfected with 500 nM of
control non-targeting or TBX21-specific On-target plus smart pool siRNAs (Thermo Fisher
Scientific) using the Lonza nucleofection 96-well plate system, according to manufacturer
specifications and as previously described (178). Cells were rapidly transferred to preheated
0

complete medium (RPMI 1640-10% FBS) and incubated for 24 hours at 37 C. Cell viability was
evaluated by vital dye exclusion (Guava Technologies). TBX21 knockdown efficiency and impact
on AICDA expression were evaluated by quantitative RT-PCR, as previously described (178).
Briefly, total RNA was extracted using the RNeasy micro kit with on-column DNA digestion
(Qiagen), according to manufacturer specifications. Total RNA was reverse transcribed and
analyzed using TaqMan probe/primer mix (Applied Biosystems) by one-step quantitative PCR
(Applied Biosystems 7500 system). Data were normalized to the housekeeping gene POLRIIA
by a comparative ΔΔCt method.

Statistics:
Paired or unpaired t-tests (two-tailed) were used to compare two groups of data. When
three or more groups were compared, one way ANOVA or repeated measures one way ANOVA,
each combined with Tukey’s multiple comparisons test, were used. Correlative relationships were
assessed using Spearman correlation. Error bars on all plots represent mean ± SEM. A P value
P< 0.05 was considered significant.

Study approval:
Written informed consent was obtained from study participants and blood/tissue samples
were collected with institutional review board approval at each collecting institution: Oregon
Health and Science University (IRB# 2470, IRB# 2832), University of Pennsylvania (IRB#809316,
IRB# 815056), Case Western University (IRB# 10-09-12), University of Toronto (REB# 12-378),
University of California San Francisco (IRB# 10-01330), Human Subjects Protection Branch
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(RV217/WRAIR#1373), The United Republic of Tanzania Ministry of Health and Social Welfare
(MRH/R.10/18/VOLL.VI/85), Tanzanian National Institute for Medical Research
(NIMR/HQ/R.8aVol.1/2013), Royal Thai Army Medical Department (IRBRTA 1810/2558), Uganda
National Council for Science and Technology– National HIV/AIDS Research Committee (ARC
084), and Uganda National Council of Science and Technology (HS 688). This work was
conducted in accordance with the principles expressed in the Declaration of Helsinki.
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